EP1091004B1 - Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation - Google Patents

Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation Download PDF

Info

Publication number
EP1091004B1
EP1091004B1 EP01200042A EP01200042A EP1091004B1 EP 1091004 B1 EP1091004 B1 EP 1091004B1 EP 01200042 A EP01200042 A EP 01200042A EP 01200042 A EP01200042 A EP 01200042A EP 1091004 B1 EP1091004 B1 EP 1091004B1
Authority
EP
European Patent Office
Prior art keywords
seq
icg
probes
iii
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP01200042A
Other languages
German (de)
English (en)
Other versions
EP1091004A2 (fr
EP1091004A3 (fr
Inventor
Geert Jannes
Rudi Rossau
Hugo Van Heuverswyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Priority to EP01200042A priority Critical patent/EP1091004B1/fr
Publication of EP1091004A2 publication Critical patent/EP1091004A2/fr
Publication of EP1091004A3 publication Critical patent/EP1091004A3/fr
Application granted granted Critical
Publication of EP1091004B1 publication Critical patent/EP1091004B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Definitions

  • the present invention relates to nucleic acid probes derived from the spacer region between the 16S and 23S ribosomal ribonucleic acid (rRNA) genes, to be used for the specific detection of Mycobacterium species in a biological sample by a hybridization procedure, as well as to nucleic acid primers to be used for the amplification of said spacer region of eubacterial organisms in a biological sample.
  • the present disclosure also relates to new spacer region sequences from which said probes or primers may be derived.
  • nucleic acid based tests essentially depends on the sensitivity and specificaty of the probes and/or primers used.
  • corner stone of this type of assay is the identification of nucleic acid sequences which are unique to the group of organisms of interest.
  • nucleic acid based tests either described in literature and/or commercially available aim at the detection of just one particular organism in a biological sample. Since most biological samples usually may contain a great variety of clinically relevant micro-organisms, a multitude of separate assays have to be performed to detect all relevant organisms possibly present. This approach would be very expensive, laborious and time-consuming. Consequently, the number of tests actually performed in most routine diagnostic labs on a particular sample is restricted to the detection of just a few of the most relevant organisms. Therefore it would be _ extremely convenient to have access to a system which enables the fast, easy and simultaneous detection of a multitude of different organisms. The more organisms that can be screened for in the same assay, the more cost-effective the procedure would be.
  • the spacer region situated between the 16S rRNA and the 23S rRNA gene also referred to as the internal transcribed spacer (ITS) is an advantageous target region for probe development for detection of pathogens of bacterial origin (International application WO 91/16454 ; Rossau et al., 1992; EP-A-0 395 292 ).
  • sequences unique to a great variety of bacterial taxa can be found in a very limited area of the bacterial genome.
  • This characteristic allows for an advantageous design of "probe-panels" enabling the simultaneous detection of a set of organisms possibly present in a particular type of a biological sample.
  • being flanked by quasi-universally conserved nucleotide sequences - more particularly located in the 3'-part of the 16S rRNA gene and the 5'-part of the 23S rRNA gene respectively - almost all spacers can be simultaneously amplified with a limited set of amplification primers.
  • specific primer sets can be derived from the spacer sequences themselves, thereby allowing species- or group-specific amplifications.
  • the 16S-23S rRNA spacer region is a relatively short (about 200 to 1000 base pairs) stretch of DNA present in one or multiple copies in the genome of almost all eubacterial organisms. If multiple copies are present in the genome of one bacterium these copies can either be identical (as is most probably the case in some Neisseria species) or may differ from each other (as is the case for E . coli) . This difference can be limited to a few nucleotides but also deletions and insertions of considerable length may be present.
  • spacer probes are only described and made publicly available for a limited number of organisms many of which were disclosed in international application WO 91/16454 .
  • a panel of pathogens e.g. a panel of pathogens possibly present in the same type of biological sample, - or a panel of pathogens possibly causing the same type of disease symptoms, which are difficult to differentiate clinically and/or biochemically, or a panel of organisms belonging to the same taxon.
  • additional probes or sets of probes located in the spacer region and enabling the identification of at least the following bacterial groups or species are required :
  • probes or sets of probes which have as target the 16S-23S rRNA spacer region, and which allow the detection and identification of at least one Mycobacterium species, and preferably more than one, of the above mentioned micro-organisms.
  • the probes or probe sets are selected in such a way that they can be used in combination with at least one other probe, preferably also originating from the 16S-23S rRNA spacer region, under the same hybridisation and wash conditions, to allow possibly the simultaneous detection of several micro-organisms in a sample.
  • lt is also an aim of the present invention to provide probes or sets of probes for the detection of Streptococcus strains.
  • the present invention to select, from the compilation of sequence data on spacer regions, specific probes and sets of probes enabling the detection and identification of a particular panel of micro-organisms at least one of which being a mycobacterium species, be it the micro-organisms belonging to a common taxon, or the micro-organisms possibly present in the same type of sample.
  • the selection procedure usually consists of a theoretical and an experimental part.
  • the different spacer sequences need to be aligned to those of the 'closest neighbours' or to the spacer sequences of other micro-organisms liable to be present in the same sample. This requires of course the sequence determination of the spacer region, as described in the examples. From the alignment, regions of divergence can be defined, from which probes with desired hybridization characteristics are designed, according to guidelines known to the man skilled in the art and specified in more detail below.
  • the designed probes need to be tested experimentally and evaluated for their usefulness under specific hybridization conditions and/or in combination with other probes.
  • Experimental testing can be done according to any hybridization method known in the art, but a preferred assay for the simultaneous testing of different probes under the same conditions is the reverse hybridization assay.
  • a specific format for reverse hybridization of different probes simultaneously used in the current invention is the LiPA (Line Probe Assay) as described below.
  • probe design especially under the fixed conditions of reverse hybridization (the same conditions for each probe) is not straightforward and probes have to be evaluated meticulously before they can be used in a reverse hybridization format. Therefor, probes cannot always be simply derived on a theoretical basis from a known gene sequence.
  • the stability of the [probe : target] nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long A and T rich sequences, by terminating the hybrids with G:C base pairs, and by designing the probe with an appropriate Tm. The beginning and end points of the probe should be chosen so that the length and %GC result in a Tm about 2-10°C higher than the temperature at which the final assay will be performed.
  • the base composition of the probe is significant because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs due to additional hydrogen bonding. Thus, hybridization involving complementary nucleic acids of higher G-C content will be stable at higher temperatures.
  • Conditions such as ionic strength and incubation temperature under which a probe will be used should also be taken into account in constructing a probe. It is known that hybridization will increase as the ionic strenght of the reaction mixture increases, and that the thermal stability of the hybrids will increase with increasing ionic strenght. On the other hand, chemical reagents, such as formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, will increase the stringency of hybridization. Destabilization of the hydrogen bonds by such reagents can greatly reduce the Tm. In general, optimal hybridization for synthetic oligonucleotide probes of about 10-50 bases in length occurs approximately 5°C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.
  • the stringency of the assay conditions determines the amount of complementarity needed between two nucleic acid strands forming a hybrid. Stringency is chosen to maximize the difference in stability between the hybrid formed with the target and the nontarget nucleic acid. In some examples of the current invention, e.g. when highly related organisms need to be differentiated, it may be necessary to detect single base pair changes. In those cases, conditions of very high stringency are needed.
  • probes should be positioned so as to minimize the stability of the [probe : nontarget] nucleic acid hybrid. This may be accomplished by minimizing the length of perfect complementarity to non-target organisms, avoiding GC rich regions of homology to non-target sequences, and by positioning the probe to span as many destabilizing mismatches as possible. Whether a probe sequence is useful to detect only a specific type of organism depends largely on the thermal stability difference between [probe:target] hybrids and (probe:nontarget) hybrids. In designing probes, the differences in these Tm values should be as large as possible (e.g. at least 2°C and preferably 5°C).
  • the length of the target nucleic acid sequence and, accordingly, the length of the probe sequence can also be important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be significantly better than another which differs merely by a single base. While it is possible for nucleic acids that are not perfectly complementary to hybridize, the longest stretch of perfectly complementary base sequence will normally primarily determine hybrid stability. While oligonucleotide probes of different lengths and base composition may be used, oligonucleotide probes preferred in this invention are between about 10 to 50 bases in length and are sufficiently homologous to the target nucleic acid.
  • hybridization is the association of two single strands of complementary nucleic acids to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid that it will be less able to participate in formation of a new hybrid. There can be intramolecular and intermolecular hybrids formed within the molecules of one type of probe if there is sufficient self complementarity. Such structures can be avoided through careful probe design.
  • the probes of the present invention are designed for attaining optimal performance under the same hybridization conditions so that they can be used in sets for simultaneous hybridization; this highly increases the usability of these probes and results in a significant gain in time and labour.
  • all probes should be adapted accordingly by adding or deleting a number of nucleotides at their extremities. It should be understood that these concommitant adaptations should give rise to essentially the same result, namely that the respective probes still hybridize specifically with the defined target. Such adaptations might also be necessary if the amplified material should be RNA in nature and not DNA as in the case for the NASBA system.
  • the hybridization conditions can be monitored relying upon several parameters, such as the nature and concentration of the components of the media, and the temperatures under which the hybrids are formed and washed.
  • the hybridization and wash temperature is limited in upper value depending on the sequence of the probe (its nucleic acid composition, kind and length).
  • hybridization temperatures can range from 45°C to 55°C, with a preferred hybridization temperature of 50°C.
  • a preferred wash medium contains 3 x SSC and 20% formamide, and preferred wash temperatures are the same as the preferred hybridization temperatures, i.e. preferably between 45°C and 55°C, and most preferably 50°C.
  • the temperatures at which the probes can be used to obtain the required specificity should be changed according to known relationships, such as those described in the following reference: Hames B and Higgins S (eds.). Nucleic acid hybridization. A practical approach, IRL Press, Oxford, U.K., 1985 .
  • the selected nucleic acid probes derived from the 16S-23S rRNA spacer region and described by the present invention are listed in Table 1a (SEQ ID NO 1 to 64, 175 to 191, 193 to 201, and 210 to 212), provided that at least one of the probes is selected from the group consisting of SEQ ID NO 1-33, 175-191, 260 and 261.
  • some of these probes show a better sensitivity and/or specificity than others, and the better probes are therefore preferentially used in methods to detect the organism of interest in a biological sample.
  • a set of probes including the less specific and/or less sensitive probes may be very informative (see e.g. example 7).
  • spacer is an abbreviated term referring to the 16S-23S rRNA internal transcribed spacer region.
  • probe refers to single stranded sequence-specific oligonucleotides which have a sequence which is sufficiently complementary to hybridize to the target sequence to be detected.
  • spacer probe refers to a probe as defined above having a sequence which is sufficiently complementary to hybridize to a target sequence which is located in the spacer region(s) of the organism (or group of organisms) to be detected.
  • probes are 70%, 80%, 90%, or more than 95% homologous to the exact complement of the target sequence to be detected.
  • target sequences are either genomic DNA or precursor RNA, or amplified versions thereof.
  • these probes are about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides.
  • the nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridization characteristics.
  • any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U).
  • the probes according to the invention can be formed by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by cleaving the latter out from the cloned plasmids upon using the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight.
  • the probes according to the present invention can also be synthesized chemically, for instance by the conventional phospho-triester method.
  • nucleic acid sequences can form a perfect base-paired double helix with each other.
  • homologous as used in the current application is synonymous for identical: this means that polynucleic acids which are said to be e.g. 80% homologous show 80% identical base pairs in the same position upon alignment of the sequences.
  • polynucleic acid corresponds to either double-stranded or single-stranded cDNA or genomic DNA or RNA containing at least 10, 20, 30, 40 or 50 contiguous nucleotides.
  • a polynucleic acid which is smaller than 100 nucleotides in length is often also referred to as an oligonucleotide.
  • Single stranded polynucleic acid sequences are always represented in the current invention from the 5' end to the 3' end.
  • the term 'closest neighbour' means the taxon which is known or expected to be most closely related in terms of DNA homology and which has to be differentiated from the organism of interest.
  • the expression 'desired hybridization characteristics' means that the probe only hybridizes to the DNA or RNA from organisms for which it was designed, and not to DNA or RNA from other organisms (closest neighbours or organisms liable to be present in the same sample). In practice, this means that the intensity of the hybridization signal is at least two, three, four, five, ten or more times stronger with the target DNA or RNA from the organisms for which the probes were designed, as compared to non-target sequences.
  • taxon-specific hybridization or “taxon-specific probe” means that the probe only hybridizes to the DNA or RNA from the taxon for which it was designed and not to DNA or RNA from other taxa.
  • taxon can refer to a complete genus or a sub-group within a genus, a species or even subtype within a species (subspecies, serovars, sequevars, biovars).
  • primers refers to the fact that said primers only amplify the spacer region from these organisms for which they were designed, and not from other organisms.
  • the probes selected as being “preferential” show a sensitivity and specificity of more than 80%, preferably more than 90% and most preferably more than 95%.
  • primer refers to a single stranded DNA oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied.
  • the length and the sequence of the primer must be such that they allow to prime the synthesis of the extension products.
  • the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use such as temperature and ionic strenght. The fact that amplification primers do not have to match exactly with the corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al., 1990).
  • the amplification method used can be either polymerase chain reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR; Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli et al., 1990; Compton, 1991), transcription-based amplification system (TAS; Kwoh et al., 1989), strand displacement amplification (SDA; Duck, 1990; Walker et al., 1992) or amplification by means of Q ⁇ replicase (Lizardi et al., 1988; Lomeli et al., 1989) or any other suitable method to amplify - nucleic acid molecules known in the art.
  • PCR polymerase chain reaction
  • LCR Landgren et al., 1988; Wu & Wallace, 1989
  • NASBA nucleic acid sequence-based amplification
  • TAS transcription-based amplification system
  • SDA
  • oligonucleotides used as primers or probes may also comprise nucleotide analogues such as phosphorothioates (Matsukura et al., 1987), alkylphosphorothioates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984).
  • nucleotide analogues such as phosphorothioates (Matsukura et al., 1987), alkylphosphorothioates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984).
  • solid support can refer to any substrate to which an oligonucleotide probe can be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low.
  • the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead).
  • a membrane e.g. nylon or nitrocellulose
  • a microsphere bead
  • modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH 2 groups, SH groups, carboxylic groups, or coupling with biotin, haptens or proteins.
  • labelled refers to the use of labelled nucleic acids. Labelling may be carried out by the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. (1988) or Bej et al. (1990) or by the use of labelled primers, or by any other method known to the person skilled in the art.
  • the nature of the label may be isotopic ( 32 P, 35 S, etc.) or non-isotopic (biotin, digoxigenin, etc.).
  • sample may be any biological material taken either directly from the infected human being (or animal), or after culturing (enrichment), or a sample taken from food or feed.
  • Biological material may be e.g. expectorations of any kind, broncheolavages, blood, skin tissue, biopsies, lymphocyte blood culture material, colonies, etc.
  • Said samples may be prepared or extracted according to any of the techniques known in the art.
  • Detection and identification of the target material can be performed by using one of the many electrophoresis methods, hybridization methods or sequencing methods described in literature and currently known by men skilled in the art.
  • a very convenient and advantageous technique for the simultaneous detection of nucleic acids possibly present in biological samples is the Line Probe Assay technique.
  • the Line Probe Assay (LiPA) is a reverse hybridization format (Saiki et al., 1989) using membrane strips onto which several oligonucleotide probes (including negative or positive control oligonucleotides) can be conveniently applied as parallel lines.
  • the LiPA technique provides a very rapid and user-friendly hybridization test. Results can be read within 4 h. after the start of the amplification. After amplification during which usually a non-isotopic label is incorporated in the amplified product, and alkaline denaturation, the amplified product is contacted with the probes on the membrane and the hybridization is carried out for about 1 to 1,5 h. Consequently, the hybrids formed are detected by an enzymatic procedure resulting in a visual purple-brown precipitate.
  • the LiPA format is completely compatible with commercially avilabe scanning devices, thus rendering automatic interpretation of the results possible. All those advantages make the LiPA format liable for use in a routine setting.
  • the LiPA format is not only an advantageous tool for identification and detection of pathogens at the species level but also at higher or lower taxonomical levels.
  • probe-configurations on LiPA strips can be selected in such a manner that they can detect a complete genus (e.g. Neisseria , Listeria, etc.) or can identify subgroups within a genus (e.g. subgroups in the Mycobacterium avium - intracellulare - scrofulaceum complex) or can in some cases even detect subtypes (subspecies, serovars, sequevars, biovars, etc. whatever is clinically relevant) within a species.
  • a complete genus e.g. Neisseria , Listeria, etc.
  • subgroups within a genus e.g. subgroups in the Mycobacterium avium - intracellulare - scrofulaceum complex
  • subtypes subspecies, serovars, sequevars, biovars
  • probes can be combined on one strip also offers the possibility to conveniently cope with a lack of sensitivity due to sequence heterogenity in the target region of the group of organisms to be detected. Due to this heterogenity, two or more probes may be required to positively identify all organisms of the particular group. These probes can be applied to membrane strips at different locations and the result is interpreted as positive if at least one of these probes is positive. Alternatively these probes can be applied as a mixture at the same location, hereby reducing the number of lines on a strip. This reduction may be convenient in order to make the strip more concise or to be able to extend the total number of probes on one strip.
  • This approach would considerably simplify the manufacturing procedures of the LiPA-strips.
  • probes with nucleotide sequences A and B are both required to detect all strains of taxon X.
  • a probe can be synthesized having the nucleotide sequence AB. This probe will have the combined characteristics of probes A and B.
  • the LiPA system can be considered as a preferential format for a hybridization method wherein several organisms need to be-detected simultaneously in a sample.
  • the LiPA system is a preferred format for a selection method for the experimental evaluation and selection of theoretically designed probes.
  • any other hybridization assay whereby different probes are used under the same hybridization and wash conditions can be used for the above-mentioned detection and/or selection methods.
  • the procedure to be followed for the detection of one or more organisms in a sample using the LiPA format is outlined below :
  • the amplification system used may be more or less universal, depending on the specific application needed.
  • the spacer region of most if not all organisms of eubacterial origin will be amplified.
  • the same result may be obtained by using a combination of different sets of primers with reduced universality (multiplex amplification, i.e. an amplification procedure in which two or more primer sets are used simultaneously in one and the same reaction mixture).
  • the spacers may be appropiate to amplify not all organisms present in the sample but more specifically, beforehand defined taxa. This may be achieved using specific primers located either in less conserved parts of the flanking genes of the spacers (e.g. MYCP1-5 for amplification of the spacer region of mycobacteria) or located in the spacers themselves (e.g. LIS-P1-P7 , BRU-P1-4, CHTR-P1-2 and YEC-P1-2 for specific amplification of the spacer region(s) of Listeria species, Brucella species, Chlamydia trachomatis, and Yersinia enterocolitica respectively).
  • specific primers located either in less conserved parts of the flanking genes of the spacers (e.g. MYCP1-5 for amplification of the spacer region of mycobacteria) or located in the spacers themselves (e.g. LIS-P1-P7 , BRU-P1-4, CHTR-P
  • the present disclosure thus provides a method for detection and identification of at least one micro-organism, or for the simultaneous detection of several micro-organisms in a sample, comprising the steps of:
  • the probes as mentioned in table 1a are all selected in such a way that they show the desired hybridization characteristics at a hybridization and wash temperature of 50°C in a preferred hybridization and wash medium of 3X SSC and 20% formamide,
  • equivalents of a probe also called “variants” or “homologues” or “obvious derivatives” refers to probes differing in sequence from any of the probes specified in table 1 either by addition to or removal from any of their respective extremities of one or several nucleotides, or by changing one or more nucleotides within said sequences, or a combination of both, provided that said equivalents still hybridize with the same RNA or DNA target as the corresponding unmodified probe sequence. Said equivalents share at least 75% homology, preferably more than 80%, most preferably more than 85% homology with the corresponding unmodified probe sequence.
  • the disclosure also provides for a method to select taxon-specific probes from the spacer region sequence(s) of said taxon, said probes being selected such that they show their desired hybridization characteristics under unified hybridization and wash conditions.
  • unified conditions means that these conditions are the same for the different probes enabling the detection of different taxa.
  • the present invention provides a method as described above wherein at least 2 micro-organisms are detected simultaneously of which at least one strain of Mycobacterium in a sample.
  • the set of probes as described in step (iii) is comprising at least two probes being selected from the sequences of table 1a, or equivalents thereof.
  • the set of probes as described in step (iii) is comprising at least one probe being selected from the sequences of table 1a, or equivalents thereof, and at least one taxon-specific probe derived from any of the spacer sequences as represented in figs. 1-103 .
  • the set of probes as described in step (iii) is comprising at least two taxon-specific probes derived from any of the spacer sequences as represented in figs. 1-103 .
  • the present disclosure also provides for a method as described above, wherein the probes as specified in step (iii) are combined with at least one other probe, preferentially also from the 16S-23S rRNA spacer region, enabling the simultaneous detection of different pathogenic bacteria liable to be present in the same sample.
  • the organisms of clinical relevance present in biological samples may vary considerably depending on the origin of the sample.
  • the most common pathogenic bacteria which may be found in sputum samples, or in samples originating from the respiratory tract, are :
  • a LiPA-strip harbouring spacer-probes enabling the detection of most if not all of these organisms would be extremely benificial for reasons explained above.
  • probes of the present invention may be combined with at least one of the probes of WO 91/16454 , or their obvious derivatives as specified in WO 91/16454 .
  • Neisseria gonorrheoae NGI1: CGATGCGTCGTTATTCTACTTCGC NGI2: TTCGTTTACCTACCCGTTGACTAAGTAAGCAAAC
  • Neisseria meningitidis NMI1: GGTCAAGTGTGACGTCGCCCTG NMI2: GTTCTTGGTCAAGTGTGACGTC NMI3: GCGTTCGTTATAGCTATCTACTGTGC NMI4: TGCGTTCGATATTGCTATCTACTGTGCA NMI5: NMI6: TTTGCCTAACATTCCGTTGACTAGAACATCAGAC
  • BCI2 TTGATGTTTAAACTTGCTTGGTGGA Bordetella pertussis
  • BPI1 CCACACCCATCCTCTGGACAGGCTT Haemophilus
  • step (iii) comprises at least one probe chosen from the following spacer probes: MYC-ICG-1: ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) MAJ-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22: TGAGGG
  • the above mentioned probes of the invention are designed for the detection of Mycobacterium species (SEQ ID NO 1 to 33 and 175 to 191), of Pseudomonas aeruginosa (SEQ ID NO 34 to 38), of Mycoplasma species (SEQ ID NO 49 to 52), of Staphylococcus aureus (SEQ ID NO 53 to 56) and of Acinetobacter baumanii (SEQ ID NO 57 and 58).
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the disclosure also relates to a method as described above, wherein said sample is a sample taken from the cerebrospinal fluid, and wherein the set of probes as described in step (iii) comprises at least one probe chosen from the following spacer probes: MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) LIS-ICG 1 : CAAGTAACCGAGAATCATCTGAAAGTGAATC (SEQ ID NO 39) LMO-ICG 1 : AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (
  • probes of the invention are designed for the detection of Mycobacterium species, and more particularly Mycobacterium tuberculosis (SEQ ID NO 1 to 5), and of Listeria species, more particularly Listeria monocytogenes (SEQ ID NO 39 to 42).
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the disclosure also relates to a method as described above, wherein said sample is a sample taken from the urogenital tract, and wherein the set of probes as described in step (iii) comprises at least one probe chosen from the following spacer probes: CHTR-ICG 1 : GGAAGAAGCCTGAGAAGGTTTCTGAC (SEQ ID NO 45) CHTR-ICG 2 : GCATTTATATGTAAGAGCAAGCATTCTATTTCA (SEQ ID NO 46) CHTR-ICG 3 : GAGTAGCGTGGTGAGGACGAGA (SEQ ID NO 47) CHTR-ICG 4 : GAGTAGCGCGGTGAGGACGAGA (SEQ ID NO 201) CHPS-ICG 1 : GGATAACTGTCTTAGGACGGTTTGAC (SEQ ID NO 48) MGE-ICG 1 : CACCCATTAATTTTTTCGGTGTTAAAACCC (SEQ ID NO 51) Mycoplasma-ICG : CAAAACTGAAAACGACAATCTTTCTAGTTCC
  • the above mentioned probes of the invention are designed for the detection of Chlamydia species (SEQ ID NO 45 to 48 and 201) and of Mycoplasma species (SEQ ID NO 51 and 52).
  • At least two, three, four, five, six or seven of said probes are used simultaneously.
  • the disclosure also relates to a method as described above, wherein said sample is a sample taken from food, and wherein the set of probes as defined in step (iii) comprises at least one probe chosen from the following spacer probes: LIS-ICG 1 : CAAGTAACCGAGAATCATCTGAAAGTGAATC (SEQ ID NO 39) LMO-ICG 1 : AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG 2 : TGAGAGGTTAGTACTTCTCAGTATGTTTGTTC (SEQ ID NO 41) LMO-ICG 3 : AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) LIV-ICG 1 : GTTAGCATAAATAGGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAAGTAGTGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAA
  • the above mentioned probes of the disclosure are designed for the detection of Listeria species (SEQ ID NO 39 to 44), of Staphylococcus species (SEQ ID NO 53 to 56), of Brucella species (SEQ ID NO 59, 60, 193 and 194), of Salmonella species (SEQ ID NO 61 to 64) and of Yersinia enterocolitica (SEQ ID NO 198 to 200).
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the disclosure also relates to a method as described above, wherein said sample is a sample taken from the gastrointestinal tract of a patient, and wherein the set of probes as defined in step (iii) comprises at least one probe chosen from the following spacer probes: SALM-ICG 1 : CAAAACTGACTTACGAGTCACGTTTGAG (SEQ ID NO 61) SALM-ICG 2 : GATGTATGCTTCGTTATTCCACGCC (SEQ ID NO 62) STY-ICG 1- : GGTCAAACCTCCAGGGACGCC (SEQ ID NO 63) SED-ICG 1 : GCGGTAATGTGTGAAAGCGTTGCC (SEQ ID NO 64) YEC-ICG 1 : GGAAAAGGTACTGCACGTGACTG (SEQ ID NO 198) YEC-ICG 2 : GACAGCTGAAACTTATCCCTCCG (SEQ ID NO 199) YEC-ICG 3 : GCTACCTGTTGATGTAATGAG
  • the above mentioned probes of the invention are designed to detect Salmonella species (SEQ ID NO 61 to 64) and Yersinia enterocolitica (SEQ ID NO 198 to 200).
  • At least two, three, four, five, six or seven of said probes are used simultaneously
  • the disclosure also relates to the use of the selected probes or their equivalents for the detection of specific bacterial taxa, said taxa being either a complete genus, or a subgroup within a genus, a species, or even a subtype within a species.
  • step (iii) comprises hybridizing to at least two of the following probes: MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) MAI-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11: GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGAG
  • sequences represented by SEQ ID NO 76-110 and 157-174 are new.
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the preferred restricted set of probes are those probes which showed a sensitivity and specificity of more than 80%, preferably more than 90%, most preferably more than 95%, under the specific hybridization conditions as described in the examples section.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium tuberculosis complex strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 76 provided said probe hybridizes specifically to the M . tuberculosis complex.
  • the M . tuberculosis complex comprises M . tuberculosis , M. bovis , M . bovis BCG, M . africanum and M. microti strains.
  • SEQ ID NO 76 The sequence represented in SEQ ID NO 76 is new.
  • At least two, or three of said probes are used simultaneously.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium strains from the MAIS-complex, wherein step (iii) comprises hybridizing to at least one of the following probes: MAI-I CG-1: CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1: CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTT
  • the MAIS complex as defined in this invention comprises all strains of M . avium , M . intracellulare and M . scrofulaceum and all strains closely related to the above mentioned species and not clearly belonging to another defined Mycobacterium species.
  • the latter group of strains are defined in this invention as "MIC strains" ( M . intracellulare complex).
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the disclosure provides for a method as described above, to detect and identify one or more M . avium and M. paratuberculosis strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 77 and 78 provided said probe hybridizes specifically to M . avium or M . paratuberculosis .
  • step (iii) comprises hybridizing to at least one of the following probes: MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) or to equivalents of said probes, and/or to any probe
  • sequences as represented in SEQ ID NO 77 and 78 are new.
  • this embodiment uses both probes in combination.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium intracellulare strains and MIC-strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MAI-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1 : CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14)
  • sequences as represented in SEQ ID NO 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99 are new.
  • At least two, three, four, five, six, seven, eight or more of said probes are used simultaneously.
  • the disclosure provides for a method as described above, to detect and identify one or more Mycobacterium intracellulare strains in a sample, wherein step (iii) comprises hybridizing to at least the following probes : MIN-ICG-1: GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 89 provided said probe hybridizes specifically to M . intracellulare strains.
  • the disclosure provides for a method as described above, to detect and identify one or more Mycobacterium scrofulaceum strains in a sample, wherein step (iii) comprises hybrdizing to the following probe: MSC-ICG-1: TCGGCTCGTTCTGAGTGGTGTC (SEQ ID NO 24) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 100 provided said probe hybridizes specifically to M . scrofulaceum.
  • SEQ ID NO 100 The sequence as represented in SEQ ID NO 100 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium kansasii strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MKA-ICG-1: GATGCGTTTGCTACGGGTAGCGT (SEQ ID NO 25) MKA-ICG-2: GATGCGTTGCCTACGGGTAGCGT (SEQ ID NO 26) MKA-ICG-3 : ATGCGTTGCCCTACGGGTAGCGT (SEQ ID NO 27) MKA-ICG-4 : CGGGCTCTGTTCGAGAGTTGTC (SEQ ID NO 28) MKA-ICG-5 : CCCTCAGGGATTTTCTGGGTGTTG (SEQ ID NO 182) MKA-ICG-6 : GGACTCGTCCAAGAGTGTTGTCC (SEQ ID NO 183) MKA-ICG-7 : TCGGGCTTGGCCAGAGCTGTT (SEQ ID NO 184) MKA-ICG-8 : TCGGGCT
  • sequences as represented in SEQ ID NO 101, 167, 168 and 169 are new.
  • At least two, three or four of said probes are used simultaneously.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium chelonae strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MCH-ICG-1 : GGTGTGGACTTTGACTTCTGAATAG (SEQ ID NO 29) MCH-ICG-2 : CGGCAAAACGTCGGACTGTCA (SEQ ID NO 30) MCH-ICG-3 : GGTGTGGTCCTTGACTTATGGATAG (SEQ ID NO 210) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 102, 103 or 174 provided said probe hybridizes specifically to M . chelonae. According to another preferential embodiment, these three probes are used in combination.
  • sequences as represented in SEQ ID NO 102, 103 and 174 are new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium gordonae strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MGO-ICG-1 : AACACCCTCGGGTGCTGTCC (SEQ ID NO 31) MGO-ICG-2 : GTATGCGTTGTCGTTCGCGGC (SEQ ID NO 32) MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33) and more preferably to: MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 104, 105 or 106 provided said probe hybridizes specifically to M . g ordonae.
  • sequences as represented in SEQ ID NO 104 to 106 are new.
  • At least two or three of said probes are used simultaneously.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium ulcerans strains or Mycobacterium marinum strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MUL-ICG-1: GGTTTCGGGATGTTGTCCCACC (SEQ ID NO 175) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 157 provided said probe hybridizes specifically to M. ulcerans and M. marinum.
  • SEQ ID NO 157 The sequence as represented in SEQ ID NO 157 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium genavense strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MGV-ICG-1: CGACTGAGGTCGACGTGGTGT (SEQ ID NO 176) MGV-ICG-2 : GGTGTTTGAGCATTGAATAGTGGTTGC (SEQ ID NO 177) MGV-ICG-3 : TCGGGCCGCGTGTTCGTCAAA (SEQ ID NO 211) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 158, 159, 160, 161 or 162 provided said probe hybridizes specifically to M . genavense.
  • sequences as represented in SEQ ID NO 158 to 162 are new.
  • M . genavense includes M . genavense strains sensu strictu and a group of closely related strains called M . simiae -like.
  • the former group of strains can be detected specifically with probe MGV-ICG-1 while the latter group hybridizes specifically with probe MGV-ICG-3.
  • Probe MGV-ICG-2 detects both groups.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium xenopi strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MXE-ICG-1: GTTGGGCAGCAGGCAGTAACC (SEQ ID NO 178) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 163 provided said probe hybridizes specifically to M . xenopi.
  • sequence as represented in SEQ ID NO 163 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium simiae strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MSI-ICG-1 : CCGGCAACGGTTACGTGTTC (SEQ ID NO 179) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 164 or 165 provided said probe hybridizes specifically to M . simiae.
  • SEQ ID NO 164 or 165 The sequence as represented in SEQ ID NO 164 or 165 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium fortuitum strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MFO-ICG-1 : TCGTTGGATGGCCTCGCACCT (SEQ ID NO 180) MFO-ICG-2 : ACTTGGCGTGGGATGCGGGAA (SEQ ID NO 181) or to equivalents of said probes or to any probe derived from SEQ ID NO 166 provided said probe hybridizes specifically to M . fortuitum.
  • SEQ ID NO 166 The sequence as represented in SEQ ID NO 166 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium celatum strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MCE-ICG-1 : TGAGGGAGCCCGTGCCTGTA (SEQ ID NO 190) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 170 provided said probe hybridizes specifically to M. celatum .
  • sequence as represented in SEQ ID NO 170 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium haemophilum strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MHP-ICG-1 : CATGTTGGGCTTGATCGGGTGC (SEQ ID NO 191) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 171, 172 or 173 provided said probe hybridizes specifically to M . haemophilum.
  • sequences as represented in SEQ ID NO 171 to 173 are new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium malmoense strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MML-ICG-1 : CGGATCGATTGAGTGCTTGTCCC (SEQ ID NO 188) MML-ICG-2 : TCTAAATGAACGCACTGCCGATGG (SEQ ID NO 189) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 107 provided said probe hybridizes specifically to M . malmoense .
  • SEQ ID NO 107 The sequence as represented in SEQ ID NO 107 is new.
  • the disclosure provides for a method as described above to detect and identify one or more Mycobacterium strains in a sample, wherein step (iii) comprises hybridizing to at least one of the following probes: MYC-ICG-1: ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) or to equivalents of said probes.
  • both probes are used in combination.
  • step (iii) comprises hybridizing to at least one of the following probes: MPN-ICG 1 : ATCGGTGGTAAATTAAACCCAAATCCCTGT (SEQ ID NO 49) MPN-ICG 2 : CAGTTCTGAAAGAACATTTCCGCTTCTTTC (SEQ ID NO 50) MGE-ICG 1 : CACCCATTAATTTTTTCGGTGTTAAAACCC (SEQ ID NO 51) Mycoplasma-ICG : CAAAACTGAAAACGACAATCTTTCTAGTTCC (SEQ ID NO 52) or to equivalents of said probes, and/or to any probe derived from SEQ ID N0 124 or 125 provided said probe hybridizes specifically with Mycoplasma species.
  • At least two three or four of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: MPN-ICG 1 : ATCGGTGGTAAATTAAACCCAAATCCCTGT (SEQ ID NO 49) MPN-ICG 2 : CAGTTCTGAAAGAACATTTCCGCTTCTTTC (SEQ ID NO 50) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 125 provided said probe hybridizes specifically to Mycoplasma pneumoniae. According to a preferred embodiment, both these probes are used in combination.
  • SEQ ID NO 125 The sequence as represented in SEQ ID NO 125 is new.
  • the disclosure invention provides for a method as described above to detect and identify one or more Mycoplasma genitalium strains in a sample, wherein step (iii) comprises hybridizing to the following probe: MGE-ICG1 : CACCCATTAATTTTITCGGTGTTAAAACCC (SEQ ID NO 51) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 124 provided said probe hybridizes specifically to Mycoplasma genitalium.
  • SEQ ID NO 124 The sequence as represented in SEQ ID NO 124 is new.
  • step (iii) comprises hybridizing to at least one of the following probes: PA-ICG1: TGGTGTGCTGCGTGATCCGAT (SEQ ID NO 34) PA-ICG 2: TGAATGTTCGTGGATGAACATTGATT (SEQ ID NO 35) PA-ICG 3 : CACTGGTGATCATTCAAGTCAAG (SEQ ID NO 36) PA-ICG 4 : TGAATGTTCGT(G/A)(G/A)ATGAACATTGATTTCTGGTC (SEQ ID NO 37) PA-ICG 5: CTCTTTCACTGGTGATCATTCAAGTCAAG (SEQ ID NO 38) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 111, 112, 113, 114 or 115 provided said probe hybridizes specifically to Pseudomonas strains.
  • At least two, three or four of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: PA-ICG1: TGGTGTGCTGCGTGATCCGAT (SEQ ID NO 34) PA-ICG2: TGAATGTTCGTGGATGAACATTGATT (SEQ ID NO 35) PA-ICG 3 : CACTGGTGATCATTCAAGTCAAG (SEQ ID NO 36) PA-ICG 4: TGAATGTTCGT(G/A)(G/A)ATGAACATTGATTTCTGGTC (SEQ ID NO 37) PA-ICG 5 : CTCTTTCACTGGTGATCATTCAAGTCAAG (SEQ ID NO 38) and most preferably to at least one of the following probes: PA-ICG1: TGGTGTGCTGCGTGATCCGAT (SEQ ID NO 34) PA-ICG 4: TGAATGTTCGT(
  • SEQ ID NO 111 The sequence as represented in SEQ ID NO 111 is new.
  • At least two, three, four or five of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: STAU-ICG1: TACCAAGCAAAACCGAGTGAATAAAGAGTT (SEQ ID NO 53)
  • STAU-ICG 2 CAGAAGATGGGGAATAACGTGAC (SEQ ID NO 54)
  • STAU-ICG 3 AACGAAGCCGTATGTGAGCATTTGAC (SEQ ID NO 55)
  • STAU-ICG 4 GAACGTAACTTCATGTTAACGTTTGACTTAT (SEQ ID NO 56) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 139, 140, 141, 142 ,143 or 144 provided said probe hybridizes specifically to Staphylococcus species.
  • sequences as represented in SEQ ID NO 139 to 144 are new.
  • At least two, three or four of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one, and preferably both of the following probes: STAU-ICG 3 : AACGAAGCCGTATGTGAGCATTTGAC (SEQ ID NO 55) STAU-ICG 4 : GAACGTAACTTCATGTTAACGTTTGACTTAT (SEQ ID NO 56) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 139, 140, 141, 142 or 143 provided said probe hybridizes specifically to Staphylococcus aureus. According to a preferred embodiment, both these probes are used in combination.
  • step (iii) comprises hybrdizing to any probe derived from SEQ ID NO 144 as long as this probe can be caused to hybridize specifically to Staphylococcus epidermidis.
  • step (iii) comprises hybridizing to at least one of the following probes: ACI-ICG1: GCTTAAGTGCACAGTGCTCTAAACTGA (SEQ ID NO 57) ACI-ICG 2 : CACGGTAATTAGTGTGATCTGACGAAG (SEQ ID NO 58) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 126, 127, 128, 129 or 130 provided said probe hybridizes specifically to Acinetobacter sp. According to a preferred embodiment, both these probes are used in combination.
  • sequences as represented in SEQ ID NO 126 to 130 are new.
  • step (iii) comprises hybridizing to at least one of the following probes: ACI-ICG 1 : GCTTAAGTGCACAGTGCTCTAAACTGA (SEQ ID NO 57) ACI-ICG2: CACGGTAATTAGTGTGATCTGACGAAG (SEQ ID NO 58) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 126 provided said probe hybridizes specifically to Acinetobacter baumanii. According to a preferred embodiment, both these probes are used in combination.
  • step (iii) comprises hybridizing to at least one of the following probes: LIS-ICG 1 : CAAGTAACCGAGAATCATCTGAAAGTGAATC (SEQ ID NO 39) LMO-ICG 1 : AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG 2 : TGAGAGGTTAGTACTTCTCAGTATGTTTGTTC (SEQ ID NO 41) LMO-ICG 3 : AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) LIV-ICG 1 : GTTAGCATAAATAGGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAAGTAGTGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAAGTAGTGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAAGTAGTGTA
  • Listeria species encompass Listeria species sensu strictu, and a group of closely related organisms referred to as " Listeria -like organisms". The latter group can be specifically recognized by probe LISP-ICG 1.
  • sequences as represented in SEQ ID NO 116, 118 to 121 and 213 to 215 are new.
  • At least two, three, four, five or six of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: LMO-ICG 1 :AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG2 : TGAGAGGTTAGTACTTCTCAGTATGTTTGTTC (SEQ ID NO 41) LMO-ICG 3 : AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) and most preferably to the following probe: LMO-ICG 3: AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 120 provided said probe hybridizes specifically to Listeria monocytogenes.
  • step (iii) comprises hybridizing to at least one of the following probes: LMO-ICG 1 :AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG2 : TGAGAGGTTAGTACTTCTCAG
  • At least two, or three of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: BRU-ICG 1 : CGTGCCGCCTTCGTTTCTCTTT (SEQ ID NO 59) BRU-ICG 2 : TTCGCTTCGGGGTGGATCTGTG (SEQ ID NO 60) BRU-ICG 3 : GCGTAGTAGCGTTTGCGTCGG (SEQ ID NO 193) BRU-ICG 4 : CGCAAGAAGCTTGCTCAAGCC (SEQ ID NO 194) and most preferably to at least one of the following probes: BRU-ICG 2 : TTCGCTTCGGGGTGGATCTGTG (SEQ ID NO 60) BRU-ICG 3 : GCGTAGTAGCGTTTGCGTCGG (SEQ ID NO 193) BRU-ICG 4 : CGCAAGAAGCTTGCTCAAGCC (SEQ ID NO 194) or to equivalents of said
  • sequences as represented in SEQ ID NO 131, 132 and 154 are new.
  • step (iii) comprises hybridizing to at least one of the following probes: SALM-ICG 1: CAAAACTGACTTACGAGTCACGTTTGAG (SEQ ID NO 61) SALM-ICG 2 : GATGTATGCTTCGTTATTCCACGCC (SEQ ID NO 62) STY-ICG1 : GGTCAAACCTCCAGGGACGCC (SEQ ID NO 63) SED-ICG 1 : GCGGTAATGTGTGAAAGCGTTGCC (SEQ ID NO 64) and most preferably to the following probe: SALM-ICG 1 : CAAAACTGACTTACGAGTCACGTTTGAG (SEQ ID NO 61) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 133, 134, 135, 136, 137 or 138 provided said probe hybridizes specifically to Salmonella strains.
  • sequences as represented in SEQ ID NO 133 to 138 are new.
  • At least two, three, or four of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: CHTR-ICG 1 : GGAAGAAGCCTGAGAAGGTTTCTGAC (SEQ ID NO 45) CHTR-ICG 2 : GCATTTATATGTAAGAGCAAGCATTCTATTTCA (SEQ ID NO 46) CHTR-ICG 3: GAGTAGCGTGGTGAGGACGAGA (SEQ ID NO 47) CHTR-ICG 4 : GAGTAGCGCGGTGAGGACGAGA (SEQ ID NO 201) CHPS-ICG 1 : GGATAACTGTCTTAGGACGGTTTGAC (SEQ ID NO 48) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 122, 123 or 197 provided that said probe hybridizes specifically to Chlamydia strains.
  • At least two, three, four or five of said probes are used simultaneously.
  • step (iii) comprises hybridizing to at least one of the following probes: CHTR-ICG 1 : GGAAGAAGCCTGAGAAGGTTTCTGAC (SEQ ID NO 45) CHTR-ICG 2: GCATTTATATGTAAGAGCAAGCATTCTATTTCA (SEQ ID NO 46) CHTR-ICG 3 : GAGTAGCGTGGTGAGGACGAGA (SEQ ID NO 47) CHTR-ICG 4 : GAGTAGCGCGGTGAGGACGAGA (SEQ ID NO 201) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 123 or 197 provided said probe hybridizes specifically to Chlamydia trachomatis.
  • sequences as represented in SEQ ID NO 123 and 197 are new.
  • At least two, three or four of said probes are used simultaneously.
  • the disclosure provides for a method as described above to detect and identify one or more Chlamydia psittaci strains in a sample, wherein step (iii) comprises hybridizing to at least the following probe: CHPS-ICG 1 : GGATAACTGTCTTAGGACGGTTTGAC (SEQ ID NO 48) or to equivalents of said probe, and/or to any probe derived from SEQ ID NO 122 provided said probe hybridizes specifically to Chlamydia psittaci.
  • SEQ ID NO 122 The sequence of SEQ ID NO 122 is new.
  • step (iii) comprises hybridizing to any probe derived from SEQ ID NO 145, 146, 147, 148, 149, 150, 151, 152 or 153 provided said probe hybridizes specifically to Streptococcus strains, or equivalents of these probes.
  • sequences_as represented in SEQ ID NO 145, 146, 147, 148, 149, 150, 151, 152 or 153 are new.
  • step (iii) comprises hybridizing to at least one of the following probes : YEC-ICG 1 : GGAAAAGGTACTGCACGTGACTG (SEQ ID NO 198) YEC-ICG 2: GACAGCTGAAACTTATCCCTCCG (SEQ ID NO 199) YEC-ICG 3 : GCTACCTGTTGATGTAATGAGTCAC (SEQ ID NO 200) or to equivalents of said probes, and/or to any probe derived from SEQ ID NO 195 or 196, provided said probe hybridizes specifically to Yersinia enterocolitica.
  • sequences as represented in SEQ ID NO 195 and 196 are new.
  • the invention provides for primers allowing the specific amplification of the spacer region for only those beforehand defined taxa.
  • step (ii) comprises amplification of the 16S-23S rRNA spacer region or a part of it, using at least one of the following primers: CHTR-P1 : A.AGGTTTCTGACTAGGTTGGGC (SEQ ID NO 69) CHTR-P2 : GGTGAAGTGCTTGCATGGATCT (SEQ ID NO 70) or equivalents of these primers, said equivalents differing in sequence from the above mentioned primers by changing one or more nucleotides, provided that said equivalents still amplify specifically the spacer region or part of it from Chlamydia trachomatis.
  • both primers are used.
  • step (ii) comprises amplification of the 16S-23S rRNA spacer region or a part of it, using at least one of the following primers: LIS-P 1 : ACCTGTGAGTTTTCGTTCTTCTC (SEQ ID NO 71) LIS-P2 : CTATTTGTTCAGTTTTGAGAGGTT (SEQ ID NO 72) LIS-P3 : ATTTTCCGTATCAGCGATGATAC (SEQ ID NO 73) LIS-P4 : ACGAAGTAAAGGTTGTTTTTCT (SEQ ID NO 74) LIS-P5 : GAGAGGTTACTCTCTTTTATGTCAG (SEQ ID NO 75) LIS-P6 : CTTTTATGTCAGATAAAGTATGCAA (SEQ ID NO 202) LIS-P7 : CGTAAAAGGGTATGATTATTTG (SEQ ID NO 203) or equivalents of these primers:
  • the disclosure also relates to a method as described above to detect and identify specifically Mycobacterium species in a sample, wherein step (ii) comprises amplification of the 16S-23S rRNA spacer region or a part of it, using at least one of the following primers: MYC-P1: TCCCTTGTGGCCTGTGTG (SEQ ID NO 65) MYC-P2: TCCTTCATCGGCTCTCGA (SEQ ID NO 66) MYC-P3: GATGCCAAGGCATCCACC (SEQ ID NO 67) MYC-P4: CCTCCCACGTCCTTCATCG (SEQ ID NO 68) MYC-P5: CCTGGGTTTGACATGCACAG (SEQ ID NO 192) or equivalents of these primers, said equivalents differing in sequence from the above mentioned primers by changing one or more nucleotides, provided that said equivalents still amplify specifically the spacer region or part of it from Mycobacterium species.
  • step (ii) comprises amplification of the 16S-23S rRNA spacer region or part of it, using at least one of the following primers : BRU-P1 : TCGAGAATTGGAAAGAGGTC (SEQ ID NO 204) BRU-P2: AAGAGGTCGGATTTATCCG (SEQ ID NO 205) BRU-P3: TTCGACTGCAAATGCTCG (SEQ ID NO 206) BRU-P4: TCTTAAAGCCGCATTATGC (SEQ ID NO 207) or equivalents of these primers, said equivalents differing in sequence from the above-mentioned primers by changing one or more nucleotides, provided that said equivalents still amplify specifically the spacer region of part of it from Brucella species.
  • step (ii) comprises amplification of the 16S-23S rRNA spacer region or part of it, using at least one of the following primers : YEC-P 1 : CCTAATGATATTGATTCGCG (SEQ ID NO 208) YEC-P2: ATGACAGGTTAATCCTTACCCC (SEQ ID NO 209) or equivalents of these primers, said equivalents differing in sequence from the above-mentioned primers by changing one or more nucleotides, provided that said equivalents still amplify specifically the spacer region of part of it from Yersinia enterocolitica species.
  • the disclosure also provides for a composition comprising at least one of the probes and/or primers as defined above.
  • composition may comprise any carrier, support, label or diluent known in the art for probes or primers, more particularly any of the labels or supports detailed in the definitions section.
  • the invention relates more partcularly to isolated probes and primers, as specified in Table 1a or any of the primers as specified in Table 1b.
  • the present disclosure relates also to new spacer region sequences as defined above and as set out in figures 1-103 (SEQ ID NO 76 to 154, SEQ m NO 157 to 174, SEQ ID NO 195 to 197 and SEQ ID NO 213 to 215).
  • the invention provides for a reverse hybridization method comprising any of the probes as defined above, wherein said probes are immobilized on a known location on a solid support, more preferably on a membrane strip.
  • the invention provides for a kit for the detection and identification of at least one Mycobacterium species, or the simultaneous detection and identification of several micro-organisms in a sample, comprising the following components:
  • Pseudomonas aeruginosa is a significant human pathogen, usually in the context of serious underlying disease. It is also a major cause of nosocomial infections, which are characteristically prone to resistance to antimicrobial agents. This gram-negative, non-fermentative rod can be responsible for different clinical manifestations, like wound infections, bacteremia, respiratory and urinary tract infections, and is also a major cause of morbidity and mortality in patients with cystic fibrosis.
  • Pseudomonas species are currently differentiated based on growth characteristics and several biochemical features implying a time schedule of 24h to 72h to get a correct identification of the pathogen.
  • DNA probes to study Pseudomonas aeruginosa are already described and are mainly used for epidemiological typing (Ogle et al., 1987; Samadpour et al., 1988; McIntosh et al., 1992). However, none of these probes have been derived from the 16S-23S spacer.
  • the 16S-23S RNA gene spacer region and a part of the 23S rRNA gene was amplified with conserved primers (upper primer: TGGGGTGAAGTCGTAACAAGGTA , SEQ ID NO 155; lower primer: CCTTTCCCTCACGGTACTGGT, SEQ ID NO 156) using the polymerase chain reaction for the following species :
  • a Not I recognition site was added to the lower primer. After purification and digestion of the fragment with Not I, the amplicon was cloned in a Eco RV/ Not I digested pBluescript Ski plasmid vector.
  • Sequencing of the 16S-23S rRNA gene spacer region was performed according the dideoxy-chain terminating chemistry either using double stranded plasmid DNA combined with primers located in the plasmid vector or directly on the PCR products after purification combined with internal PCR primers.
  • Fig. 36 to 40 represent the nucleotide sequence of the 16S-23S rRNA gene spacer regions from the different Pseudomonas species described above. For P . fluorescens only partial sequence information was obtained.
  • oligonucleotide-probes From the nucleic acid sequence of the spacer from P . aeruginosa strain 5669 five oligonucleotide-probes were chosen and chemically synthetized. The sequences of the oligonucleotides are the following :
  • oligonucleotide-probes Specificity and sensitivity testing of the oligonucleotide-probes was carried out using a reverse hybridization assay. Genomic DNA of the different bacteria tested was amplified using biotinylated primers (idem primers as for cloning procedure, see above). The obtained amplicon, spanning the 16S-23S rRNA gene spacer region, was denatured and hybridized to a membrane-strip onto which the different oligonucleotide probes were immobilized in a line-wise fashion (LiPA).
  • LiPA line-wise fashion
  • Hybrids were detected using a streptavidine conjugate coupled to alkaline phosphatase and the probes were visualized through a precipitation reaction using NBT (nitrobluetetrazolium) and BCIP (bromo-chloro-indolylphosphate).
  • probes PA1, PA2 and PA3 are given in table 4 and show that probes PA1 and PA3 were 100% specific for Pseudomonas aeruginosa and hybridized to all the strains tested.
  • the hybridization signal with probe PA3 at 50° C was not optimal, so the oligonucleotide-probe was improved by adding some additional nucleotides to the specific probe.
  • This newly designed probe is PA5.
  • Oligonucleotide-probe PA2 hybridized only to 5 out of 17 P . aeruginosa strains tested. Direct sequencing of the 16S-23S rRNA gene spacer region of the strains which did not hybridize to these probes, showed some heterogeneity between different strains. Two mismatches were seen in comparison to the first developed PA2 probe. To overcome this heterogeneity between different strains in the region of probe PA2 a new probe PA4 was designed. This probe is degenerated at the position of the mismatches and some additional nucleotides were added to improve the hybridization signal at 50° C.
  • PA4 PA-ICG 4 : TGAATGTTCGT(G/A)(G/A)ATGAACATTGATTTCTGGTC
  • mycobacterial species may be involved in serious human infectious disease. Notorious examples are Mycobacterium tuberculosis and Mycobacterium leprae. Recently other species such as M. avium, M. intracellulare and M kansasii have been more frequently encountered as human pathogens especially in immunocompromised hosts.
  • LiPA-test was developed which allows for the simultaneous and reliable detection and differentiation of a number of Mycobacterium species and groups.
  • the sets of probes used to achieve these goals were all derived from the 16S-23S rRNA spacer region. The methods used are analogous to those mentioned in example 1.
  • the 16S-23S rRNA spacer region of a number of mycobacterial strains was sequenced.
  • the obtained sequences were compared to each other and to those already known from literature (e.g. Frothingham et al., 1993, 1994; Kempsell et al., 1992; Suzuki et al., 1988; EP-A-0395292 ; Van der Giessen et al., 1994; ) or from publicly accessable data banks.
  • the corresponding sequences are represented in fig.1 to 35 (SEQ ID NO 76 to SEQ ID NO 110).
  • the probes derived from these data were all adjusted in such a way that the desired hybridization-behaviour was obtained using unified hybridization and wash conditions (i.e. 3xSSC, 20% deionized formamide, 50°C).
  • the set of adjusted probes used for hybridization to different mycobacterial strains is represented in table 1a, SEQ ID NO 1-33. Please note that the probe nomenclature used in this example is an abbreviated version of the one used in table 1a: i.e. the letters "ICG" have always been omitted.
  • the strains tested could be assigned to one of the following species or species groups: M. tuberculosis complex, M. avium, M. intracellulare or M.
  • the M. tuberculosis complex harbours all strains belonging to M. tuberculosis, M bovis, M. africanum and M. microti.
  • the probes Mtb1, Mtb2 and Mtb3 hybridize with DNA originating from all M. tuberculosis complex strains tested. None of the other strains tested hybridized with these probes at the conditions used.
  • M. tuberculosis complex strains as is the case with all other mycobacterial strains tested, hybridize with either the myc1 or the myc22 probe or both.
  • the latter two probes are designed as general Mycobacterium probes, either alone or in combination with each other.
  • paratuberculosis should in fact be considered as belonging to one geno-species (Rogal et al., 1990), M. avium ssp. avium and M. avium ssp. paratuberculosis.
  • MIC strains are genotypically highly related organisms, which, according to sequence data of the 16S-23S rRNA spacer region, belong to a distinct cluster which is separate from other Mycobacterium species. M. avium and M. scrofulaceum are their closest relatives. Almost all strains tested which are generally referred to as M. avium complex (MAC) strains (the former MAIS-complex) can be found in the MIC group.
  • M. avium complex (MAC) strains the former MAIS-complex
  • Type MIC 1 harbours M intracellulare s.s., together with some other MAC-strains. All MIC 1 type isolates, without exception, hybridize to the following probes: myc1/myc22, mail and mac1. The following probes can be used to make further subdivisions within the MIC 1 group : mil11, min1, min2 to 2222, mil22 and mhef1 .
  • M intracellulare sensu stricto strains (type MIC 1.1.a ) can be distinguished from other subtypes in this group by virtue of probe min 1 which is positive only for this group of strains. All strains of type MIC 1.1.a strains are positive when tested with the M . intracellulare probe of the Gen-Probe Rapid Diagnostic system for MAC. Type MIC 1.1.b and MIC 1.2 harbour strains which are highly related to M . intracellulare. They can be differentiated by using probes mil11 and mil22 (see Table 3). Further subdivision within these groups was not attempted although this could be achieved by using the probes : min2, min22, min222 and min2222. Further subdivision might be of value for epidemiological reasons. Only two of our collection of strains tested group as MIC 2 strains.
  • Mycobacterium lufu strain (ITG 4755).
  • the specific probe pattern generated by these strains is characterized by a positive hybridization signal with the following probes myc1/myc22, mail, mil22, mah1 and mal1. Variable hybridization results are obtained with probes min2222, mac1 and mhef1. The other probes are negative. It is not unlikely that MIC 2 would eventually prove to be a heterogeneous group when more strains of this type are being identified. The variable probes may help in a further differentiation, if this would become relevant.
  • Type MIC 3 groups a fairly high number of MAC-strains which are rather remotely related to M. iniracellulare s.s.
  • MIC 3 subtypes hybridize to probes myc1/myc22, mail, mil22 and mco1. A positive signal with the latter probe (mcol) is characteristic for MIC 3 strains. Variable hybridization results are obtained with the following probes : mac1, mhef1 and mah1. MIC 3 can be further subdivided into four subtypes by using three probes : mth11, mth2 and mef11. Probe mth2 is specific for type MIC 3.1 which encompasses a group of highly related MAC-strains isolated from immuno- compromised human beings.
  • Type MIC 4 is a collection of "MAIS" strains (including M malmoense) which are remotely related to M. intracellulare.
  • MAIS M malmoense
  • Probes mka3 and mka4 are specific for M. kansasii; i.e. a distinct positive signal is obtained on the LiPA strip when amplified DNA from the M kansasii strains is used in the hybridization whilst with all other organisms tested the signal is absent.
  • sequences of probes mka1 and mka2 are not absolutely complementary to the target sequence (3 and 1 mismatches, respectively), these probes also proved to be useful since they hybridized exclusively to M kansasii DNA and not to any other mycobacterial DNA tested under the conditions used (50°C, 3xSSC, 20% formamide). This illustrates that probes not necessarilly have to match perfectly to the target to be useful, and that modifications in sequence and length may be allowed up to a certain degree.
  • the species M. chelonae encompasses M. chelonae ssp. chelonae and M. chelonae ssp. abscessus strains.
  • the spacer region was sequenced for one strain of each subspecies and small differences were noticed (SEQ ID NO 103 and SEQ ID NO 102).
  • Probes mch1 and mch2 hybridize to both strains. All other probes are negative for these 2 strains except for myc1/myc22.
  • chelonae 94-330 both obtained from the Institute of Tropical Medecine in Antwerp, Belgium, it appeared that they did not hybridize to probe mch1. This was confirmed by sequencing the spacer region of these two strains (SEQ ID N0 184). Cluster analysis of the spacer region with other mycobacteria revealed that M . chelonae strains can be subdivided in two groups. A third probe mch3 was designed to specifically detect this second group of strains, to which 94-379 and 94-330 belong.
  • DNA probes derived from the 16S-23S rRNA spacer region can be helpful in differentiating different groups of strains, which belong to the same species according to the classical identification methods, and possibly can be used to detect and describe new species within the mycobacteria.
  • mch2 detects all M. chelonae strains
  • mch1 and mch3 differentiate between different subgroups.
  • MIC 1.1.a intracellulare 4199, 4208, 5701, 5880, 5906, 5908, 5909, 5913, 5915, 5917, 5918, 5920, 5921, 5924, 5925, 5929, 8713, 8717, 8718, 8720, 8721, 8722, 8732, 8740, 8741, 8742, 8744,8747,8749 MIC 1.1.b 8694,8745,8754 8708 5513,8743 MIC 1.2 8710, 8711, 8712, 8714, 8715, 8716, 8725, 8729, 8733, 8737, 8746, 8751, 8752 5919 8695 8748 MIC 2 5922 4755 (M.
  • Listeria species are a group of Gram-positive rods widely spread in nature. Within this group it seems that only L . monocytogenes is pathogenic to humans and animal. L. monocytogenes is the causative agent of listeriosis, giving rise to meningitis, abortions, encephalitis and septicemia. Immunocompromised individuals, newborn infants and pregnant women are high risk groups for this foodborn disease. Most cases have been caused by the consumption of food of animal origin, particularly soft cheeses. Therefore, the presence of L. monocytogenes should be excluded from food. For safety measurements, in some countries, the absence of all Listeria species is required in food products.
  • L . monocytogenes Several DNA probes are already described for the identification of L . monocytogenes. Some probes are derived from genes responsible for the pathogenicity of the organism, for instance the listeriolysin O gene (Datta et al., 1993) or the invasion-associated-protein (iap) (Bubert et al., 1992).
  • the spacer region was amplified using the polymerase chain reaction and subsequently cloned in a suitable plasmid vector following the same procedures as in example 3.
  • the sequence of the spacer region between the 16S and 23S rRNA gene was determined using the cloned material originating from the 800 bp PCR fragment and this was done for the three described Listeria species.
  • Fig. 41 to 43 show the sequences of the different short spacer regions obtained.
  • the sequence of this short spacer region of L. monocytogenes was also retrieved from the EMBL databank (LMRGSPCR).
  • probe LIS 1 can detect all described Listeria species, but also that the species-specific probes cross-hybridize to each other. Hence, from this short spacer region probes with sufficient specificity could not be found.
  • Fig. 45 shows the sequence obtained for this species. This sequence information was also obtained for L . seeligeri (see fig. 46 ) and partial sequence information of the large spacer region was obtained for L . ivanovii (see fig. 44 ).
  • the oligonucleotide-probes, LIS1 for detection of all Listeria species and LMO3 for specific detection of L . monocytogenes were immobilized on a membrane strip and hybridized to labeled amplicons, containing the 16S-23S rRNA spacer region, derived from different organisms. The hybridization results are shown in the following table.
  • Primers LIS-P and LIS-P2 are upper primers, whereas LIS-P3 and LIS-P4 are lower primers. These primersets amplify the smaller 16S-23S rRNA spacer region as well as the larger spacer of Listeria species (except L . grayi and L . murrayi) . If needed these primers can be used in a nested PCR assay where LIS-P1/LIS-P4 are the outer primers and LIS-P2/LIS-P3 are the inner primers.
  • LMO-ICG-3 For the specific detection of Listeria monocytogenes probe LMO-ICG-3 was designed and derived from the large 16S-23S rRNA spacer region. In order to specifically amplify only this large spacer region for an improved detection of this pathogen directly in samples a set of primers was derived from the part of sequence information from the large 16S-23S rRNA spacer region that is not present in the smaller rRNA spacer. For this aim, primers LIS-P5. and LIS-P6 are used as the upper primers and LIS-P7 is used as the lower primer.
  • LIS-P1 ACCTGTGAGTTTTCGTTCTTCTCTC 71
  • LIS-P2 CTATTTGTTCAGTTTTGAGAGGTT 72
  • LIS-P3 ATTTTCCGTATCAGCGATGATAC 73
  • LIS-P4 ACGAAGTAAAGGTTGTTTTTCT 74
  • LIS-P5 GAGAGGTTACTCTCTTTTATGTCAG 75
  • LIS-P6 CTTTTATGTCAGATAAAGTATGCAA 202
  • LIS-P7 CGTAAAAGGGTATGATTATITG 203
  • Isolate MB 405 seemed to contain at least 3 different 16S-23S rRNA spacer regions which were cloned and sequenced. Following alignment with Listeria spp. an oligonucleotide-probe was chosen te specifically detect Listeria -like strains: LISP-ICG-1 : CGTTTTCATAAGCGATCGCACGTT Reverse hybridization reactions of this probe with the 16S-23S rRNA spacer regions of Listeria spp. showed that there was no cross-hybridization.
  • Chlamydia trachomatis is a small obligate intracellular gram-negative bacterium, which has 15 serovars (A-K, Ba, L1, L2, and L3) distinguished by the major outer membrane protein (MOMP) and contains a cryptic plasmid required for intracellular growth.
  • A-K and Ba serovars constitute the trachoma biovar, while the L1, L2, and L3 serovars constitute the LGV biovar.
  • Serovars A, B, Ba, and C are commonly associated with trachoma, the leading cause of preventable blindness worldwide.
  • the D-K serovars are found mainly in sexually transmitted infections and are the major cause of cervicitis and pelvic inflammatory disease in women, and urethritis and epididymitis in men.
  • Serovars L1, L2 and L3 are involved in lymphogranuloma venereum, a rare sexually transmitted disease.
  • a nonisotopic DNA probe assay (Gen-Probe PACE; Woods et al., 1990) that detects chlamydial rRNA is commercially available.
  • PCR polymerase chain reaction
  • Detection was targeted at either the cryptic plasmid (Loeffelholz et al., 1992), or the omp 1 gene, which encodes for the major outer membrane protein (Taylor-Robinson et al., 1992).
  • PCR has higher sensitivity and specificity (Ossewaarde et al., 1992). None of these assays make use of DNA probes derived from the 16S-23S rRNA gene spacer region.
  • RNA cistron For a Chlamydia trachomatis L2 and a Chlamydia psittaci 6BC strain, a part of the ribosomal RNA cistron, containing the 16S-23S rRNA spacer region was amplified using conserved primers (see example 1) and subsequently cloned in a plasmid vector. The 16S-23S rRNA spacer region was sequenced using the dideoxychain terminating chemistry.
  • oligonucleotide-probes were immobilized in a line-wise fashion on a membrane strip and subsequently used in a reverse hybridization assay with biotinylated PCR products, containing the 16S-23S rRNA spacer region, as target.
  • Hybridizations were done in a solution of 3xSSC and 20% formamide (FA) at a temperature of 50°C.
  • probes CHTR1, CHTR2 and CHTR2 are specific for Chlamydia trachomatis and probe CHPS1 is specific for Chlamydia psittaci.
  • Chlamydia trachomatis Several clinical isolates, obtained from the SSDZ, Delft, Netherlands, identified as Chlamydia trachomatis using conventional methods were tested in a reverse hybridization assay with the different oligonucleotide-probes. All Chlamydia trachomatis specific probes gave a positive hybridization signal and none of the isolates reacted with the Chlamydia psittaci probe. For some clinical isolates the CHTR2 probe reacted significantly weaker than CHTR1 or CHTR3. The spacer region of one of these isolates (94 M 1961) was sequenced (SEQ ID NO 197) and the sequence revealed one mismatch with the spacer sequence of strain L2.
  • CHTR4 was derived from this new spacer sequence : CHTR-ICG-4: GAGTAGCGCGGTGAGGACGAGA (SEQ ID NO 201) This probe gives a stronger hybridization signal than CHTR2 with some clinical isolates from Chlamydia trachomatis. It can be used alone, or in combination with the CHTR2 probe (e.g. both probes applied in one LiPA-line).
  • CHTR-P1 AAGGTTTCTGACTAGGTTGGGC 69
  • CHTR-P2 GGTGAAGTGCTTGCATGGATCT 70
  • EXAMPLE 6 Mycoplasma pneumoniae and Mycoplasma genitalium
  • Mycoplasmas are a group of the smallest prokaryotes known that are able to grow in cell-free media, lack a cell wall, and have very small genomes with a low G+C content. More than 100 different species have been isolated from humans, animals, plants, and insects.
  • mycoplasmas have been recognized either as pathogenic organisms or as commensals.
  • the best known pathogen is Mycoplasma pneumoniae, the causative agent of primary atypical pneumonia, especially in children and young adults.
  • the diagnosis of M. pneumoniae has been based on the direct isolation by the culture method or on the detection of specific antibodies against M. pneumoniae in the patient's serum.
  • Mycoplasma genitalium Another pathogen, first isolated from urethral specimens from patients with nongonococcal urethritis, has been described as Mycoplasma genitalium.
  • This mycoplasma has several properties in common with M. pneumoniae. Both species are pathogenic, and both possess the capability to adhere to erythrocytes, various tissue cells, glass, and plastic surfaces.
  • M. genitalium and M. pneumoniae share antigens, giving rise to extensive cross-reactions in serological tests. The observation that M. genitalium could also be found in respiratory tract specimens from patients with pneumonia and isolated from a mixture with M. pneumoniae has raised questions to the possible pathogenicity of M. genitalium.
  • M. pneumoniae -specific PCR assays have been reported using the P1 adhesin gene (Buck et al., 1992) and the 16S rRNA gene (Kuppeveld et al., 1992). Specific PCR assays for M. genitalium were described using sequences from the adhesin gene and the 16S rRNA gene.
  • the spacer sequences of clinical isolates of M. pneumoniae and M. genitalium were determined. They are shown in fig. 49 to 50 . The sequences show some differences to those from other strains of the same species deposited in the EMBL databank (MPMAC and MGG37 respectively). Based on this information four probes were derived: one general Mycoplasma probe, two M. pneumoniae specific, and one M. genitalium specific probe :
  • the probes were applied to LiPA strips and hybridized under standard conditions (3X SSC, 20% formamide at 50°C) to amplified spacer material from four M. pneumoniae strains, one M. genitalium strain and twenty-two non- Mycoplasma species strains.
  • the general probe hybridized only to the five Mycoplasma strains tested, while the specific probes hybridized only to strains of the species for which they were designed.
  • probes were derived from the 16S-23S rRNA spacer region sequence. For the above mentioned species this information was obtained through direct sequencing of PCR products or after cloning of the PCR-amplified spacer region. The sequences obtained are represented in fig. 80 to 97 , and in fig. 38 for M. malmoense.
  • the sequences of the spacer region of the above-mentioned mycobacterial species were compared and aligned to those already described in example 2 or in publicly available sources. From the regions of divergence, species-specific DNA probes were designed. The probes were selected and designed in such a way that the desired hybridization behaviour (i.e. species-specific hybridization) was obtained under the same conditions as those specified for the other mycobacterial probes mentioned in example 2, i.e. 3X SSC, 20% deionized formamide, 50°C. This allows simultaneous detection of at least two, and possibly all, of the mycobacterial species described in the current invention.
  • oligonucleotide probes were designed from the spacer region sequence of respectively M. ulcerans , M. genavense, M. xenopi, M. simiae, M. fortuitum, M. malmoense, M. celatum and M. haemophilum:
  • the probes were immobilized on a LiPA strip and hybridized with amplified biotinylated material derived from a set of representative mycobacterial species as described in example 2. Amplification of the spacer region was carried out by PCR using a primer set as described in example 2. The different strains used for specificity testing are shown in table 8 together with the hybridization results obtained. The strains were obtained from the collection of the Institute for Tropical Medicine, Antwerp, Belgium.
  • the probes tested specifically detected M. simiae, M. xenopi, M. fortuitum, M. malmoense, M. celatum and M. haemophilum respectively and showed no cross-hybridization with the other mycobacterial species tested.
  • these probes allow a specific detection of mycobacterial species which were not further identifiable using the set of DNA probes described in example 2.
  • malmoense was classified in example 2 as a "MIC 4"-type, while the other species mentioned above were only hybridizing to the general probes MYC1/MYC22 for the genus Mycobacterium, and were thus classified in example 2 as "other mycobacterial species".
  • M. genavense isolates reacted with MGV-ICG1 and MGV-ICG2, and not with MSI-ICG1 designed for M. simiae, closely related to M. genavense.
  • MGV-ICG3 TCGGGCCGCGTGTTCGTCAAA
  • DNA probes derived from the 16S-23S spacer region can be helpful in differentiating different groups of strains, which are also found indeterminate by classical taxonomic criteria.
  • the use of these DNA probes may possilby lead to the description of new (sub)species within mycobacteria.
  • the MGV-1 probe would react only with M. genavense strains sensu stricto
  • MGV-3 probe would react only with the intermediate " M. simiae -like" strains
  • MGV-2 probe would detect both types of strains.
  • M. marinum The probe MUL-ICG-1 reacted with all M. ulcerans strains tested, but also showed cross-hybridization with M. marinum strain ITG 7732. Sequencing of the spacer region of this M. marinum strain indeed revealed an identical sequence to that of M. ulcerans strain 1837 (see fig. 80 ). Further differentiation between M. marinum and M. ulcerans can be done using a probe from the 16S-rRNA gene of M. ulcerans, part of which is co-amplified with the spacer region when primers MYC P1-P5 are used for amplification.
  • a species-specific 16S rRNA probe for M. ulcerans which can work under the same hybridization conditions as the spacer probes for mycobacterium species differentiation, is for example: TGGCCGGTGCAAAGGGCTG (SEQ ID NO 216)
  • probes derived from the spacer region it is also possible, and sometimes necessary, to combine the spacer probes with probes derived from other gene sequences, e.g. the 16S rRNA gene.
  • these additional probes are selected such that they show the desired hybridization characteristics under the same hybridization and wash conditions as the spacer probes.
  • M. kansasii For M. kansasii, additional strains to the ones mentioned in example 2 have been tested with probes MKA-ICG-1, 2, 3 and 4 described in example 2. Since none of these probes was entirely satisfactory, additional probes were designed for M. kansasii detection. Therefor, the spacer region of some of the additional M. kansasii strains ITG 6328, 8698 and 8973 was sequenced (see fig.90 to 92 ). These strains were also obtained from the Institute of Tropical Medecine in Antwerp, Belgium. Apparently, M. kansasii strains constitute a quite heterogeneous group, with remarkable differences in the spacer sequence between different strains.
  • M. kansasii probes hybridizes with a species other than M. kansasii, as far as tested. However, due to the heterogeneous character of this species, none of the M. kansasii probes hybridizes with all M. kansasii strains. The different M. kansasii probes recognize different strains of M. kansasii. This differential hybridization may be of clinical significance. On the other hand, if detection of all M. kansasii strains is desirable, a combination of different M. kansasii probes can be envisaged.
  • Brucellosis is a very widespread and economically important zoonosis which also affects humans.
  • probes BRU-ICG 2, BRU-ICG 3 and BRU-ICG 4 are specific for Brucella spp. and can be used in a reverse hybridization assay for detection of these pathogens.
  • Probe BRU-ICG 1 cross-hybridizes with Ochrobactrum antropi and Rhizobium loti strains, which are two taxonomically highly related organisms, but which are not expected to be present in the same sample material as used for Brucella detection.
  • BRU-P1 and BRU-P2 are used as upper primers, while BRU-P3 and BRU-P4 are used as lower primers.
  • BRU-P1/BRU-4 is the outer primerset whereas the combination BRU-P2/BRU-P3 is the inner primerset.
  • BRU-P1 TCGAGAATTGGAAAGAGGTC 204
  • BRU-P2 AAGAGGTCGGATTTATCCG 205
  • BRU-P3 TTCGACTGCAAATGCTCG 206
  • BRU-P4 TCTTAAAGCCGCATTATGC 207
  • BRU-ICG 1 BRU-ICG 2
  • BRU-ICG 3 BRU-ICG 4
  • Staphylococcus aureus is the staphylococcal species most commonly associated with human and animal infections. Staphylococcus aureus strains have been identified as important etiologic agents in both community-acquired and nosocomial infections. Recently nosocomial infection with methicillin-resistant S. aureus (MRSA) appear to be increasingly prevalent in many countries. The strains belonging to this species are also causative agents of food spoilage and poisoning.
  • MRSA methicillin-resistant S. aureus
  • the oligonucleotides were immobilized on a membrane strip and following reverse hybridization with biotinylated PCR fragments, the hybrids were visualized using a colorimetric precipitation reaction.
  • probe STAU-ICG 3 and STAU-ICG 4 are specific for Staphylococcus aureus strains.
  • Probe STAU-ICG 1 reacts with all Staphylococcus spp. tested and probe STAU-ICG 2 cross-hybridizes with the S. lugdinensis strain.
  • probe STAU-ICG 3 nor probe STAU-ICG 4 detects all S. aureus strains tested, but when both probes are used simultaneously in a LiPA assay, all S. aureus strains tested hybridize with one of these probes or with both.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (28)

  1. Procédé pour la détection et l'identification d'au moins une souche de l'espèce Mycobacterium ou pour la détection simultanée de plusieurs microorganismes, parmi lesquels au moins une souche de l'espèce Mycobactarium, dans un échantillon, comprenant les étapes consistant à :
    (i) libérer, isoler et/ou concentrer les acides polynucléiques à partir du (des) microorganisme(s) à détecter dans l'échantillon ;
    (ii) si besoin est, amplifier la région espaceur de l'ARNr 16S-23S ou une partie de celle-ci, provenant du (des) microorganisme(s) à détecter dans l'échantillon, avec au moins une paire d'amorces appropriées ;
    (iii) hybrider les acides polynucléiques des étapes
    (i) ou (ii) avec un ensemble de sondes comprenant au moins deux sondes, avec lesdites sondes étant choisies parmi les sondes espaceurs suivantes : MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) MAI-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTGAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1 : CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14) MIN-ICG-222 : TGATGCGTTCGTCGAAATGTGT (SEQ ID NO 15) MIN-ICG-2222 : GGCTGATGCGTTCGTCGAAATGTGTAA (SEQ ID NO 16) MAL-ICG-1 : ACTAGATGAACGCGTAGTCCTTGT (SEQ ID NO 17) MHEF-ICG-1 : TGGACGAAAACCGGGTGCACAA (SEQ ID NO 18) MAH-ICG-1 : GTGTAATTTCTTTTTTAACTCTTGTGTGTAAGTAAGTG (SEQ ID NO 19) MCO-ICG-11 : TGGCCGGCGTGTTCATCGAAA (SEQ ID NO 20) MTH-ICG-11 : GCACTTCAATTGGTGAAGTGCGAGCC (SEQ ID NO 21) MTH-ICG-2 : GCGTGGTCTTCATGGCCGG (SEQ ID NO 22) MEF-ICO-11 : ACGCGTGGTCCTTCGTGG (SEQ ID NO 23) MSC-TCG-1 : TCGGCTCGTTCTGAGTGGTGTC (SEQ ID NO 24) MKA-ICG-1 : GATGCGTTTGCTACGGGTAGCGT (SEQ ID NO 25) MKA-ICG-2 : GATGCGTTGCCTACGGGTAGCGT (SEQ ID NO 26) MKA-ICG-3 : ATGCGTTGCCCTACGGGTAGCGT (SEQ ID NO 27) MKA-ICG-4 : CGGGCTCTGTTCGAGAGTTGTC (SEQ ID NO 28) MCH-ICG-1 : GGTGTGGACTTTGACTTCTGAATAG (SEQ ID NO 29) MCH-ICG-2 : CGGCAAAACGTCGGACTGTCA (SEQ ID NO 30) MCH-ICG-3 : GGTGTGGTCCTTGACTTATGGATAG (SEQ ID NO 210) MGO-ICG-1 : AACACCCTCGGGTGCTGTCC (SEQ ID NO 31) MGO-ICG-2 : GTATGCGTTGTCGTTCGCGGC (SEQ ID NO 32) MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33) MUL-ICG-1 : GGTTTCGGGATGTTGTCCCACC (SEQ ID NO 175) MGV-ICG-1 : CGACTGAGGTCGACGTGGTGT (SEQ ID NO 176) MGV-ICG-2 : GGTGTTTGAGCATTGAATAGTGGTTGC (SEQ ID NO 177) MOV-ICG-3 : TCGGGCCGCGTGTTCGTCAAA (SEQ ID NO 211) MXE-ICG-1 : GTTGGGCAGCAGGCAGTAACC (SEQ ID NO 178) MSI-ICG-1 : CCGGCAACGGTTACGTGTTC (SEQ ID NO 179) MFO-ICG-1 : TCGTTGGATGGCCTCGCACCT (SEQ ID NO 180) MFO-ICG-2 : ACTTGGCGTGGGATGCGGGAA (SEQ ID NO 181) MKA-ICG-5 : CCCTCAGGGATTTTCTGGGTGTTG (SEQ ID NO 182) MKA-ICG-6 : GGACTCGTCCAAGAGTGTTGTCC (SEQ ID NO 183) MKA-ICG-7 : TCGGCTTGGCCAGAGCTGTT (SEQ ID NO 184) MKA-ICG-8 : GGGTGCGCAACAGCAAGCGA (SEQ ID NO 185) MKA-ICG-9 : GATGCGTTGCCCCTACGGG (SEQ ID NO 186) MKA-ICG-10 : CCCTACGGGTAGCGTGTTCTTTTG (SEQ ID NO 187) MML-ICG-1 : CGGATCGATTGAGTGCTTGTCCC (SEQ ID NO 188) MML-ICG-2 : TCTAAATGAACGCACTGCCGATGG (SEQ ID NO 189) MCE-ICG-1 : TGAGGGAGCCCGTGCCTGTA (SEQ ID NO 190) MHP-ICG-1 : CATGTTGGGCTTGATCGGGTGC (SEQ ID NO 191) PA-ICG 1 : TGGTGTGCTGCGTGATCCGAT (SEQ ID NO 34) PA-ICG 2 : TGAATGTTCGTGGATGAACATTGATT (SEQ ID NO 35) PA-ICG 3 : CACTGGTGATCATTCAAGTCAAG (SEQ ID NO 36) PA-ICG4 : TGAATGTTCGT(G/A)(G/A)ATGAACATTGATTTCTGGTC (SEQ ID NO 37) PA-ICG 5 : CTCTTTCACTGGTGATCATCATTCAAGTCAAG (SEQ ID NO 38) LIS-ICG 1 : CAAGTAACCGAGAATCATCTGAAAGTGAATC (SEQ ID NO 39) LMO-ICG 1 : AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG 2 : TGAGAGGTTAGTACTTCTCAGTATGTTTGTTC (SEQ ID NO 41) LMO-ICG 3 : AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) LIV-ICG 1 : GTTAGCATAAATAGGTAACTATTTATGACACAAGTAAC (SEQ ID NO 43) LSE-ICG 1 : AGTTAGCATAAGTAGTGTAACTATTTATGACACAAG (SEQ ID NO 44) LISP-ICG 1 : CGTTTTCATAAGCGATCGCACGTT (SEQ ID NO 212) CHTR-ICG 1 : GGAAGAAGCCTGAGAAGGTTTCTGAC (SEQ ID NO 45) CHTR-ICG 2 : GCATTTATATGTAAGAGCAAGCATTCTATITCA (SEQ ID NO 46) CHTR-ICG 3 : GAGTAGCGTGGTGAGGACGAGA (SEQ ID NO 47) CHPS-ICG 1 : GGATAACTGTCTTAGGACGGTTTGAC (SEQ ID NO 48) MPN-ICG 1 : ATCGGTGGTAAATTAAACCCAAATCCCTGT (SEQ ID NO 49) MPN-ICG 2 : CAGTTCTGAAAGAACATTTCCGCTTCTTTC (SEQ ID NO 50) MGE-ICG 1 : CACCCATTAATTTTTTCGGTGTTAAAACCC (SEQ ID NO 51) Mycoplasma-ICG: CAAAACTGAAAACGACAATCTTTCTAGTTCC (SEQ ID NO 52) STAU-ICG 1 : TACCAAGCAAAACCGAGTGAATAAAGAGTT (SEQ ID NO 53) STAU-ICG 2 : CAGAAGATGCGGAATAACGTGAC (SEQ ID NO 54) STAU-ICG 3 : AACGAAGCCGTATGTGAGCATTTGAC (SEQ ID NO 55) STAU-ICG 4 : GAACGTAACTTCATGTTAACGTTTGACTTAT (SEQ ID NO 56) ACI-ICG 1 : GCTTAAGTGCACAGTGCTCTAAACTGA (SEQ ID NO 57) ACI-ICG 2 : CACGGTAATTAGTGTGATCTGACGAAG (SEQ ID NO 58) BRU-ICG 1 : CGTGCCGCCTTCGTTTCTCTTT (SEQ ID NO 59) BRU-ICG 2 : TTCGCTTCGGGTGGATCTGTG (SEQ ID NO 60) BRU-ICG 3 : GCGTAGTAGCGTTTOCGTCGG (SEQ ID NO 193) BRU-ICG 4 : CGCAAGAAGCTTGCTCAAGCC (SEQ ID NO 194) SALM-ICG 1 : CAAAACTGACTTACGAGTCACGTTTGAG (SEQ ID NO 61) SALM-ICG 2 : GATGTATGCTTCGTTATTCCACGCC (SEQ ID NO 62) STY-ICG 1 : GGTCAAACCTCCAGGGACGCC (SEQ ID NO 63) SED-ICG 1 : GCGGTAATGTGTGAAAGCGTTGCC (SEQ ID NO 64) YEG-ICG 1 : GGAAAAGGTACTGCACGTGACTG (SEQ ID NO 198) YEC-ICG 2 : GACAGCTGAAACTTATCCCTCCG (SEQ ID NO 199) YEC-ICG 3 : GCTACCTGTTGATGTAATGAGTCAC (SEQ ID NO 200) CHTR-ICG 4 : GAGTAGCGCGGTGAGGACGAGA (SEQ ID NO 201)
    à condition qu'au moins une des sondes soit choisie dans le groupe composé des SEQ ID n° 1 à 33, SEQ ID n° 175 à 191 et SEQ ID n° 210 et 211,
    ou bien des équivalents desdites sondes, avec lesdits équivalents différant, au niveau de leur séquence, de n'importe laquelle des sondes indiquées ci-dessus soit par ajout soit par retrait de l'une quelconque de leurs extrémités respectives d'un ou plusieurs nucléotide(s) ou par changement d'un ou plusieurs nucléotide(s) au sein desdites séquences ou bien une combinaison des deux, à condition que lesdits équivalents s'hybrident encore avec la même cible d'ARN ou d'ADN que la séquence de la sonde non modifiée correspondante.
  2. Procédé selon la revendication 1, dans lequel l'échantillon provient des voies respiratoires et dans lequel l'étape (iii) est caractérisée en ce que l'ensemble de sondes comprend au moins deux sondes choisies parmi les sondes espaceurs suivantes : MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) MAI-ICG-1 : CAACAGCAAATGATTGCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC.ICG-1 : CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14) MIN-ICG-222 : TGATGCGTTCGTCGAAATGTGT (SEQ ID NO 15) MlN-ICG-2222 : GGCTGATGCGTTCGTCGAAATGTGTAA (SEQ ID NO 16) MAL-ICG-1 : ACTAGATGAACGCGTAGTCCTTGT (SEQ ID NO 17) MHEF-ICG-1 : TGGACGAAAACCGGGTGCACAA (SEQ ID NO 18) MAH-ICG-1: GTGTAATTTCTTTTTTAACTCTTGTGTGTAAGTAAGTG (SEQ ID NO 19) MCO-ICG-11 : TGGCCGGCGTGTTCATCGAAA (SEQ ID NO 20) MTH-ICG-11 : GCACTTCAATTGGTGAAGTGCGAGCC (SEQ ID NO 21) MTH-ICG-2 : GCGTGGTCTTCATGGCCGG (SEQ ID NO 22) MEF-ICG-11 : ACGCGTGGTCCTTCGTGG (SEQ ID NO 23) MSC-ICG-1 : TCGGCTCGTTCTGAGTGGTGTC (SEQ ID NO 24) MKA-ICG-1 : GATGCGTTTGCTACGGGTAGCGT (SEQ ID NO 25) MKA-ICG-2 : GATGCGTTGCCTACGGGTAGCGT (SEQ ID NO 26) MKA-ICG-3 : ATGCGTTGCCCTACGGGTAGCGT (SEQ ID NO 27) MKA-ICG-4 : CGGGCTCTGTTCGAGAGTTGTC (SEQ ID NO 28) MKA-ICG-5 : CCCTCAGGGATTTTCTGGGTGTTG (SEQ ID NO 182) MKA-ICG-6 : GGACTCGTCCAAGAGTGTTGTCC (SEQ ID NO 183) MKA-ICG-7 : TCGGGCTTGGCCAGAGCTGTT (SEQ ID NO 184) MKA-ICG-8 : GGGTGCGCAACAGCAAGCGA (SEQ ID NO 185) MKA-ICG-9 : GATGCGTTGCCCCTACGGG (SEQ ID NO 186) MIKA-ICG-10 : CCCTACGGGTAGCGTGTTCTTTTG (SEQ ID NO 187) MCH-ICG-1 : GGTGTGGAGGAGCTGAATAG (SEQ ID NO 29) MCH-ICG-2 : CGGCAAAACGTCGGACTGTCA (SEQ ID NO 30) MCH-ICO-3 : GGTGTGGTCCTGACTTATGGATAG (SEQ ID NO 210) MGO-ICG-1 : AACACCCTCGGGTGCTGTCC (SEQ ID NO 31) MGO-ICG-2 : GTATGCGTTGTCGTTCGCGGC (SEQ ID NO 32) MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33) MUL-ICG-1 : GGTTTCGGGATGTTGTCCCACC (SEQ ID NO 175) MGV-ICG-1 : CGACTGAGGTCGACGTGGTGT (SEQ ID NO 176) MGV·ICG-2 : GGTGTTTGAGCATTGAATACITGGTTGC (SEQ ID NO 177) MGV-ICG-3 : TCGGGCCGCGTGTTCGTCAAA (SEQ ID NO 211) MXE-ICG-1 : GTTGGGCAGCAGGCAGTAACC (SEQ ID NO 178) MSI-ICG-1 : CCGGCAACGGTTACGTGTTC (SEQ ID NO 179) MFO-ICG-1 : TCGTTGGATGGCCTCGCACCT (SEQ ID NO 180) MFO·ICG-2 : ACTTGGCGTGGGATGCGGGAA (SEQ ID NO 181) MML-ICG-1 : CGGATCGATTGAGTGCTTGTCCC (SEQ ID NO 188) MML-ICG-2 : TCTAAATGAACGCACTGCCGATGG (SEQ ID NO 189) MCE-ICG-1 : TGAGGGAGCCCGTGCCTGTA (SEQ ID NO 190) MHP-ICG-1 : CATGTTGGGCTTGATCGGGTGC (SEQ ID NO 191) PA-ICG 1 : TGGTGTGCTGCGTGATCCGAT (SEQ ID NO 34) PA-ICG 2 : TGAATGTTCGTGGATGAACATTGATT (SEQ ID NO 35) PA-ICG 3 : CACTGGTGATCATTCAAGTCAAG (SEQ ID NO 36) PA-ICG 4 : TGAATGTTCGT(G/A)(G/A)ATGAACATTGATTTCTGGTC (SEQ ID NO 37) PA-ICG 5 : CTCTTTCACTGGTGATCATTCAAGTCAAG (SEQ ID NO 38) MPN-ICG 1 : ATCGGTGGTAAATTAAACCCAAATCCCTGT (SEQ ID NO 49) MPN-ICG 2 : CAGTTCTGAAAGAACATTTCCGCTTCTTTC (SEQ ID NO 50) MGE-ICG 1 : CACCCATTAATTTTTTCGGTGTTAAAACCC (SEQ ID NO 51) Mycoplasma-ICG : CAAAACTGAAAACGACAATCMCTAGTRCC (SEQ ID NO 52) STAU-ICG 1 : TACCAAGCAAAACCGAGTGAATAAAGAGTT (SEQ ID NO 53) STAU-ICG 2 : CAGAAGATGCGGAATAACGTGAC (SEQ ID NO 54) STAU-ICG 3: AACGAAGCCGTATGTGAGCATTTGAC (SEQ ID NO 55) STAU-ICG 4 : GAACGTAACTTCATGTTAACGTTTGACTTAT (SEQ ID NO 56) ACI-ICG 1 : GCTTAAGTGCACAGTGCTCTAAACTGA (SEQ ID NO 57) ACI-ICG 2 : CACGGTAATTAGTGTGATCTGACGAAG (SEQ ID NO 58)
    ou bien des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1,
    et avec lesdites sondes ou lesdits équivalents étant utilisés possiblement en combinaison avec n'importe quelle sonde détectant au moins un organisme parmi les suivants : Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis ou Bordetella pertussis.
  3. Procédé selon la revendication 1, dans lequel l'échantillon est prélevé dans le liquide céphalorachidien et dans lequel l'étape (iii) est caractérisée en ce que l'ensemble de sondes comprend au moins deux sondes choisies parmi les sondes espaceurs suivantes : MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1: GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5) LIS-ICG 1 : CAAGTAACCGAGAATCATCTGAAAGTGAATC (SEQ ID NO 39) LMO-ICG 1 : AAACAACCTTTACTTCGTAGAAGTAAATTGGTTAAG (SEQ ID NO 40) LMO-ICG 2; TGAGAGGTTAGTACTTCTCAGTATGTTTGTTC (SEQ ID NO 41) LMO-ICQ 3 : AGGCACTATGCTTGAAGCATCGC (SEQ ID NO 42) LISP-ICG 1: CGTTTTCATAAGCGATCGCACGTT (SEQ ID NO 212)
    ou bien des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1,
    et avec lesdites sondes ou lesdits équivalents étant utilisés possiblement en combinaison avec n'importe quelle sonde détectant au moins un organisme parmi les suivants : Neisseria meningitidis, Haemophilus influenzae ou Streptococcus pneumoniae.
  4. Procédé, selon la revendication 1, destiné à détecter et identifier au moins une souche de l'espèce Mycobacterium ou pour la détection simultanée de plusieurs microorganismes, parmi lesquels au moins une souche de l'espèce Mycobacterium, dans un échantillon,
    dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MYC-ICG-1: ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2) MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCGA (SEQ ID NO 3) MTB-ICG-2: GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTGTTCT (SEQ ID NO 5) MAI-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1 : CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14) MIN-ICG-222 : TGATGCGTTCGTCGAAATGTGT (SEQ ID NO 15) MIN-ICG-2222 : GGCTGATGCGTTCGTCGAAATGTGTAA (SEQ ID NO 16) MAL-ICG-1 : ACTAGATGAACGCGTAGTCCTTGT (SEQ ID NO 17) MHEF-ICG-1 : TGGACGAAAACCGGGTGCACAA (SEQ ID NO 18) MAH-ICG-1 : GTGTAATTTCTTTTTTAACTCTTGTGTGTAAGTAAGTG (SEQ ID NO 19) MCO-ICG-11 : TGGCCGGCGTGTTCATCGAAA (SEQ ID NO 20) MTH-ICG-11 : GCACTTGAATTGGTGAAGTGCGAGCC (SEQ ID NO 21) MTH-ICG-2 : GCGTGGTCTTCATGGCCGG (SEQ ID NO 22) MEF-ICQ-11 : ACGCGTGGTCCTTCGTGG (SEQ ID NO 23) MSC-ICG-1 : TCGGCTCGTTCTGAGTGGTGTC (SEQ ID NO 24) MKA-ICG-1 : GATGCGTTTGCTACGGGTAGCGT (SEQ ID NO 25) MKA-ICG-2 : GATGCGTTGCCTACGGGTAGCGT (SEQ ID NO 26) MKA-ICG-3 : ATGCGTTGCCCTACGGGTAGCGT (SEQ ID NO 27) MKA-ICG-4 : CGGGCTCTGTTCGAGAGTTGTC (SEQ ID NO 28) MKA-ICG-5 : CCCTCAGGGATTTTCTGGGTGTTG (SEQ ID NO 182) MKA-ICG-6 : GGACTCGTCCAAGAGTGTTGTCC (SEQ ID NO 183) MKA-ICG-7 : TCGGGCTTGGCCAGAGCTGTT (SEQ ID NO 184) MKA-ICG-8 : GGGTGCGCAACAGCAAGCGA (SEQ ID NO 185) MKA-ICG-9 : GATGCGTTGCCCCTACGGG (SEQ ID NO 186) MKA-ICG-10 : CCCTACGGGTAGCGTGTTCTTTTG (SEQ ID NO 187) MCH-ICG-1 : GGTGTGGACTTTGACTTCTGAATAG (SEQ ID NO 29) MCH-ICG-2 : CGGCAAAACGTCGGACTGTCA (SEQ ID NO 30) MGO-TCG-1 : AACACCCTCGGGTGCTGTCC (SEQ ID NO 31) MGO-ICG-2 : GTATGCGTTGTCGTCGTTCGCGGC (SEQ ID NO 32) MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33) MUL-ICG-1 : GGTTTCGGGATGTTGTCCCACC (SEQ ID NO 175) MGV-ICG-1 : CGACTGAGGTCGACGTGGTGT (SEQ ID NO 176) MGV-ICG-2 : GGTGTTTGAGCATTGAATAGTGGTTGC (SEQ ID NO 177) MXE-ICG-1 : GTTGGGCAGGAGGCAGTAACC (SEQ ID NO 178) MSI-IGG-1 : CCGGCAACGGTTACGTGTTC (SEQ ID NO 179) MFO-ICG- 1 : TCGTTGGATGGCCTCGCACCT (SEQ ID NO 180) MFO-ICG-2 : ACTTGGCGTGGGATGCGGGAA (SEQ ID NO 181) MML-ICG-1 : CGGATCGATTGAGTGCTTGTCCC (SEQ ID NO 188) MML-ICG-2 : TCTAAATGAACGCACTGCCGATGG (SEQ ID NO 189) MCE-ICG-1 : TGAGGGAGCCCGTGCCTGTA (SEQ ID NO 190) MHP-ICG-1 : CATGTTGGGCTTGATCGGGTGC (SEQ ID NO 191)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1 ;
    (iv) détecter les hybrides formés à l'étape (iii) ;
    (v) identifier le(s) microorganisme(s) présent(s) dans l'échantillon à partir des signaux différentiels d'hybridation obtenus à l'étape (iv).
  5. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) du complexe Mycobacterium tuberculosis dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MTB-ICG-1 : GGGTGCATGACAACAAAGTTGGCCA (SEQ ID NO 3) MTB-ICG-2 : GACTTGTTCCAGGTGTTGTCCCAC (SEQ ID NO 4) MTB-ICG-3 : CGGCTAGCGGTGGCGTGTTCT (SEQ ID NO 5)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  6. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium du complexe MAIS, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MAI-ICG-1 : CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1 : CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MAV-ICG-1 : TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22 : GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2 : GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14) MIN-ICG-222 : TGATGCGTTCGTCGAAATGTGT (SEQ ID NO 15) MIN-ICG-2222 : GGCTGATGCGTTCGTCGAAATGTGTAA (SEQ ID NO 16) MAL-ICG-1 : ACTAGATGAACGCGTAGTCCTTGT (SEQ ID NO 17) MHEF-ICG-1 : TGGACAAAAACCGGGTGCACAA (SEQ ID NO 18) MAH-ICG-1 : GTGTAATTTCTTTTTTAACTCTTGTGTGTAAGTAAGTG (SEQ ID NO 19) MCO-ICG-11 : TGGCCGGCGTGTTCATCGAAA (SEQ ID NO 20) MTH-ICG-11 : GCACTTCAATTGGTGAAGTGCGAGCC (SEQ ID NO 21) MTH-ICG-2: GCGTGGTCTTCATGGCCGG (SEQ ID NO 22) MEF-ICG-11 : ACGCGTGGTCCTTCGTQG (SEQ ID NO 23) MSC-ICG-1: TCGGCTCGCTTCTGAGTGGTGTC (SEQ ID NO 24)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  7. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de M. avium et M. paratuberculosis dans un échantillon, dans lequel l'étape (iii) comprend une hybridation aux sondes suivantes ; MAV-ICG-1: TCGGTCCGTCCGTGTGGAGTC (SEQ ID NO 10) MAV-ICG-22: GTGGCCGGCGTTCATCGAAA (SEQ ID NO 11)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  8. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium intracellulare et des souches MIC dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MAI-ICG-1: CAACAGCAAATGATTGCCAGACACAC (SEQ ID NO 6) MIL-ICG-11 : GAGGGGTTCCCGTCTGTAGTG (SEQ ID NO 7) MIL-ICG-22 : TGAGGGGTTCTCGTCTGTAGTG (SEQ ID NO 8) MAC-ICG-1: CACTCGGTCGATCCGTGTGGA (SEQ ID NO 9) MIN-ICG-1 : GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12) MIN-ICG-2: GCTGATGCGTTCGTCGAAATGTGTA (SEQ ID NO 13) MIN-ICG-22 : CTGATGCGTTCGTCGAAATGTGT (SEQ ID NO 14) MIN-ICG-222 ; TGATGCGTTCGTCGAAATGTGT (SEQ ID NO 15) MIN-ICG-2222; GGCTGATGCGTTCGTCGAAATGTGTAA (SEQ ID NO 16) MAL-ICG-1 : ACTAGATGAACGCGTAGTCCTTGT (SEQ ID NO 17) MHEF-ICG-1 : TGGACGAAAACCGGGTGCACAA (SEQ ID NO 18) MAH-ICG-1 : GTGTAATTTCTTTTTTAACTCTTGTGTAAGTAAGTG (SEQ ID NO 19) MCO-ICG-11 : TGGCCGGCGTGTTCATCGAAA (SEQ ID NO 20) MTH-ICG-11 : GCACTTCAATTGGTGAAGTGCGAGCC (SEQ ID NO 21) MTH-ICG-2 : GCGTGGTCTTCATGGCCGG (SEQ ID NO 22) MEF-ICG-11 : ACGCGTGGTCCTTCGTGG (SEQ ID NO 23),
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  9. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium intracellulare dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MIN-ICG-1: GCATAGTCCTTAGGGCTGATGCGTT (SEQ ID NO 12)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  10. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium scrofulaceum dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MSC-ICG-1: TCGGCTCGTTCTGAGTGGTGTC (SEQ ID NO 24)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  11. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium kansasii dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MKA-ICG-1 : GATGCGTTTGCTACGGGTAGCGT (SEQ ID NO 25) MKA-ICG-2 : GATGCGTTGCCTACGGGTAGCGT (SEQ ID NO 26) MKA-ICG-3 : ATGCGTTGCCCTACGGGTAGCGT (SEQ ID NO 27) MKA-ICG-4 : CGGGCTCTGTTCGAGAGTTGTC (SEQ ID NO 28) MKA-ICG-5 : CCCTCAGGGATTTTCTGGGTGTTG (SEQ ID NO 182) MKA-ICG-6 : GGACTCGTCCAAGAGTTGTCC (SEQ ID NO 183) MKA-ICG-7 : TCGGGCTTGGCCAGAGCTGTT (SEQ ID NO 184) MKA-ICG-8 : GGGTGCGCAACAGCAAGCGA (SEQ ID NO 185) MKA-ICG-9 : GATGCGTTGCCCCTACGGG (SEQ ID NO 186) MKA-ICG-10 : CCCTACGGGTAGCGTGTTCTTTTG (SEQ ID NO 187)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  12. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium chelonae dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MCH-ICG-1 : GGTGTGGACTTTGACTTCTGAATAG (SEQ ID NO 29) MCH-ICG-2 : CGGCAAAACGTCGGACTGTCA (SEQ ID NO 30) MCH-ICG-3 : GGTGTGGTGGTCCTTGACTTATGGATAG (SEQ ID NO 210)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  13. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium gordonae dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MGO-ICG-1 : AACACCCTCGGGTGCTGTCC (SEQ ID NO 31) MGO-ICG-2 : GTATGCGTTGTCGTTCGCGGC (SEQ ID NO 32) MGO-ICG-5 : CGTGAGGGGTCATCGTCTGTAG (SEQ ID NO 33)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  14. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium ulcerans ou M. marinum dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MUL-ICG-1: GGTTTCGGGATGTTGTCCCACC (SEQ ID NO 175)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  15. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium genavense dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à deux sondes au moins parmi les suivantes : MGV-ICG-1 : CGACTGAGGTCGACGTGGTGT (SEQ ID NO 176) MGV-ICG-2 : GGTGTTTGAGCATTGAATAGTGGTTGC (SEQ ID NO 177) MGV-ICG-3 : TCGGGCCGCGTGTTCGTCAAA (SEQ ID NO 211)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  16. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium xenopi dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MXE-ICG-1: GTTGGGCAGCAGGCAGTAACC (SEQ ID NO 178) et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  17. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium simiae dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MSI-ICG-1: CCGGCAACGGTTACGTGTTC (SEQ ID NO 179)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  18. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium fortuitum dans un échantillon, dans lequel l'étape (iii) comprend une hybridation aux sondes suivantes : MPO-ICG-1 : TCGTTGGATGGCCTCGCACCT (SEQ ID NO 180) MFO-ICG-2 : ACTTGGCGTGGGATGCGGGAA (SEQ ID NO 181)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  19. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium celatum dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante ; MCE-ICG-1: TGAGGGAGCCCGTGCCTGTA (SEQ ID NO 190)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  20. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium haemophilum dans un échantillon, dans lequel l'étape (iii) comprend une hybridation à la sonde suivante : MHP-ICG-1: CATGTTGGGCTTGATCGGGTGC (SEQ ID NO 191)
    et à une deuxième sonde choisie parmi les séquences indiquées dans la revendication 4 ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  21. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium malmoense dans un échantillon, dans lequel l'étape (iii) comprend une hybridation aux sondes suivantes : MML-ICG-1: CGGATCGATTGAGTGCTTGTCCC (SEQ ID NO 188) MML-ICG-2: TCTAAATGAACGCACTGCCGATGG (SEQ ID NO 189)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  22. Procédé, selon la revendication 4, destiné à détecter et identifier une ou plusieurs souche(s) de Mycobacterium dans un échantillon, dans lequel l'étape (iii) comprend une hybridation aux sondes suivantes : MYC-ICG-1 : ACTGGATAGTGGTTGCGAGCATCTA (SEQ ID NO 1) MYC-ICG-22 : CTTCTGAATAGTGGTTGCGAGCATCT (SEQ ID NO 2)
    ou à des équivalents desdites sondes, avec les équivalents étant tels que définis dans la revendication 1.
  23. Procédé, selon la revendication 4, destiné à détecter et identifier spécifiquement l'espèce Mycobacterium dans un échantillon, dans lequel l'étape (ii) comprend l'amplification de la région espaceur de l'ARNr 163-233 ou d'une partie de celle-ci, en utilisant au moins une des amorces suivantes : MYC-P1 : TCCCTTGTGGCCTGTGTG (SEQ ID NO 65) MYC-P2: TCCTTCATCGGCTCTCGA (SEQ ID NO 66) MYC-P3: GATGCCAAGGCATCCACC (SEQ ID NO 67) MYC-P4: CCTCCCACGTCCTTCATCG (SEQ ID NO 68) MYC-P5: CCTGGGTTTGACATGCACAG (SEQ ID NO 192)
    ou des équivalents de ces amorces, lesdits équivalents différant, au niveau de leur séquence, des amorces mentionnées ci-dessus par changement d'un ou plusieurs nucléotide (s), à condition que lesdits équivalents amplifient encore spécifiquement la région espaceur ou une partie de celle-ci de l'espèce Mycobacterium.
  24. Composition comprenant au moins une des amorces ou au moins deux des sondes telles que définies dans les revendications 4 à 23.
  25. Sonde telle que définie dans l'une quelconque des revendications 4 à 22.
  26. Amorce telle que définie dans la revendication 23.
  27. Procédé d'hybridation inverse selon l'une quelconque des revendications 1 à 23, dans lequel les sondes sont immobilisées sur un support solide à un emplacement connu, mieux préféré sur une bande de membrane.
  28. Trousse pour la détection et l'identification d'au moins une souche de l'espèce Mycobacterium ou pour la détection et l'identification simultanées de plusieurs microorganismes, parmi lesquels au moins une souche de l'espèce Mycobacterium, dans un échantillon, comprenant les composants suivants :
    (i) quand cela est approprié, au moins une paire d'amorces appropriées permettant d'obtenir l'amplification de la région espaceur de l'ARNr 16S-235 ou d'une partie de celle-ci ;
    (ii) au moins deux des sondes définies dans la revendication 25 ;
    (iii) un tampon, ou des composants nécessaires pour élaborer le tampon, permettant d'obtenir une réaction d'hybridation entre lesdites sondes et les acides polynucléiques présents dans l'échantillon ou les produits amplifiés de ceux-ci ;
    (iv) une solution ou des composants nécessaires pour élaborer la solution, permettant d'effectuer un lavage des hybrides formés dans des conditions de lavage appropriées ;
    (v) quand cela est approprié, un moyen de détection des hybrides résultant de l'hybridation précédente.
EP01200042A 1994-06-24 1995-06-23 Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation Expired - Lifetime EP1091004B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01200042A EP1091004B1 (fr) 1994-06-24 1995-06-23 Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP94870106 1994-06-24
EP94870106 1994-06-24
EP95870032 1995-04-07
EP95870032 1995-04-07
EP95924923A EP0769068B1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
EP01200042A EP1091004B1 (fr) 1994-06-24 1995-06-23 Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP95924923A Division EP0769068B1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation

Publications (3)

Publication Number Publication Date
EP1091004A2 EP1091004A2 (fr) 2001-04-11
EP1091004A3 EP1091004A3 (fr) 2001-04-18
EP1091004B1 true EP1091004B1 (fr) 2009-02-25

Family

ID=26137770

Family Applications (5)

Application Number Title Priority Date Filing Date
EP95924923A Expired - Lifetime EP0769068B1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
EP01200045A Withdrawn EP1098006A1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
EP01200046A Withdrawn EP1098007A1 (fr) 1994-06-24 1995-06-23 Détection, identification et différentiation simultanées de taxa d'eubactériales à l'aide d'une technique d'hybridation
EP01200042A Expired - Lifetime EP1091004B1 (fr) 1994-06-24 1995-06-23 Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation
EP01200037A Withdrawn EP1088899A3 (fr) 1994-06-24 1995-06-23 Détection, identification et différentiation simultanées de taxa d'eubactériales a l'aide d'une technique d'hybridation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP95924923A Expired - Lifetime EP0769068B1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
EP01200045A Withdrawn EP1098006A1 (fr) 1994-06-24 1995-06-23 Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
EP01200046A Withdrawn EP1098007A1 (fr) 1994-06-24 1995-06-23 Détection, identification et différentiation simultanées de taxa d'eubactériales à l'aide d'une technique d'hybridation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01200037A Withdrawn EP1088899A3 (fr) 1994-06-24 1995-06-23 Détection, identification et différentiation simultanées de taxa d'eubactériales a l'aide d'une technique d'hybridation

Country Status (14)

Country Link
US (4) US6025132A (fr)
EP (5) EP0769068B1 (fr)
JP (1) JP3833703B2 (fr)
AT (2) ATE423853T1 (fr)
AU (1) AU2924695A (fr)
BR (1) BR9508101A (fr)
CA (1) CA2193101C (fr)
CZ (1) CZ291483B6 (fr)
DE (2) DE69535923D1 (fr)
DK (1) DK0769068T3 (fr)
ES (2) ES2323161T3 (fr)
HK (1) HK1037687A1 (fr)
RU (1) RU2154106C2 (fr)
WO (1) WO1996000298A1 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0452596A1 (fr) 1990-04-18 1991-10-23 N.V. Innogenetics S.A. Sondes d'hybridation provenant de régions d'espacement entre les gènes de rRNA 16S et 23S pour la détection des micro-organismes non viraux
EP0769068B1 (fr) 1994-06-24 2005-10-12 Innogenetics N.V. Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
US6001564A (en) * 1994-09-12 1999-12-14 Infectio Diagnostic, Inc. Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US20020055101A1 (en) 1995-09-11 2002-05-09 Michel G. Bergeron Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US5849488A (en) * 1996-02-27 1998-12-15 Oulutech Ltd. DNA-sequence-based diagnosis of mastitis from a milk sample
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US20030049636A1 (en) 1999-05-03 2003-03-13 Bergeron Michel G. Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
US6465638B2 (en) 1997-06-25 2002-10-15 Ortho-Clinical Diagnostics, Inc. Multiplexed PCR assay for detecting disseminated Mycobacterium avium complex infection
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
DE19739611A1 (de) * 1997-09-09 1999-03-11 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Nucleinsäure-Sequenzen und Verfahren zum Nachweis von Bakterien der Gattung Pseudomonas
AU1337099A (en) * 1997-10-29 1999-05-17 Mira Diagnostica Gmbh Method for identifying micro-organisms
US6004754A (en) * 1998-01-21 1999-12-21 Becton Dickinson And Company DNA sequence, related probes and primers for the detection of Streptococcus agalactiae
US6261769B1 (en) * 1998-03-31 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Intergenic spacer target sequence for detecting and distinguishing Chlamydial species or strains
EP1115885B1 (fr) * 1998-09-24 2008-08-20 Innogenetics N.V. Identification des micro-organismes responsables d'infections respiratoires
GB9904804D0 (en) 1999-03-02 1999-04-28 King S College London Identification of bacteria
US6821770B1 (en) 1999-05-03 2004-11-23 Gen-Probe Incorporated Polynucleotide matrix-based method of identifying microorganisms
US20030207313A1 (en) * 1999-05-29 2003-11-06 Kim Cheol Min Oligonucleotide for detection and identification of Mycobacteria
BR0014370A (pt) * 1999-09-28 2002-11-05 Infectio Diagnostic Inc Genes altamente conservados e seu uso para gerar sondas de ácido nucléico e preparadores de amplificação especìficos em espécie, especìfico em gênero, especìficos em famìlia, especìficos em grupo e universais para rapidamente detectar e identificar microorganismos algais, amebianos, bacterianos, fúngicos e parasitas de espécimes clìnicos para diagnose
US6261785B1 (en) 2000-07-27 2001-07-17 Becton, Dickinson And Company Amplification and detection of Bordetella pertussis
JP2004504068A (ja) * 2000-07-27 2004-02-12 ザ　オーストラリアン　ナショナル　ユニバーシティー コンビナトリアル・プローブ及びそのための用途
CA2461950C (fr) * 2001-11-02 2011-04-05 Gen-Probe Incorporated Compositions, procedes et equipements permettant de determiner la presence de mycoplasma pneumoniae et/ou de mycoplasma genitalium dans un echantillon pour essai
WO2003066893A1 (fr) * 2002-02-04 2003-08-14 Vermicon Ag Procede de detection specifique rapide de bacteries pathogenes presentes dans des denrees alimentaires
EP1426447A1 (fr) * 2002-12-06 2004-06-09 Roche Diagnostics GmbH Méthode de détection de bactéries pathogéniques et gram positives, sélectionné des genera Staphylococcus, Enterococcus et Streptococcus
EP1567668B1 (fr) * 2002-12-06 2009-04-29 Innogenetics N.V. Detection, identification et differentation de taxa d'eubacteriales a l'aide d'une technique d'hybridation
WO2004053156A1 (fr) * 2002-12-06 2004-06-24 Innogenetics N.V. Detection, identification et differenciation de taxa eubacteries, par dosage biologique d'hybridation
US20060099596A1 (en) * 2002-12-06 2006-05-11 Roche Molecular Systems, Inc. Multiplex assay detection of pathogenic organisms
US20040142495A1 (en) * 2002-12-16 2004-07-22 Hartman William G. Analyte detecting article and method
US7967756B2 (en) * 2003-09-18 2011-06-28 Cardiac Pacemakers, Inc. Respiratory therapy control based on cardiac cycle
TWI361490B (en) * 2003-09-05 2012-04-01 Renesas Electronics Corp A semiconductor device and a method of manufacturing the same
WO2005045074A2 (fr) * 2003-11-05 2005-05-19 Stichting Voor De Technische Wetenschappen Moyens et methodes de classification des cyanobacteries
US8227192B2 (en) 2003-11-26 2012-07-24 Advandx, Inc. Peptide nucleic acid probes for analysis of certain Staphylococcus species
EP1709198B1 (fr) * 2003-11-26 2013-08-14 AdvanDx, Inc. Sondes d'acides nucleiques peptidiques pour l'analyse de certaines especes staphylococcus
ES2320350T3 (es) * 2003-12-09 2009-05-21 Biomerieux, Inc. Procedimientos para detectar patogenos bacterianos.
US7429464B2 (en) * 2003-12-09 2008-09-30 Biomerieux, Inc. Methods for detecting bacterial pathogens
EP1692511B1 (fr) * 2003-12-09 2012-09-19 bioMerieux, Inc. Methode de recuperation de micro-organismes dans un echantillon
KR100615424B1 (ko) * 2004-01-14 2006-08-25 김철민 마이코플라즈마 및 유사 균종의 유전자형 감별을 위한올리고뉴클레오티드, 이를 포함하는 마이크로어레이와이를 이용한 균종 검출 방법
ES2597841T3 (es) * 2004-02-06 2017-01-23 Fujirebio Europe N.V. Detección, identificación y diferenciación de especies de Proteus utilizando la región espaciadora
JP4788942B2 (ja) * 2004-02-23 2011-10-05 独立行政法人産業技術総合研究所 特定生物種検出のためのデオキシリボザイム
US7332597B2 (en) 2004-06-28 2008-02-19 University Of Kentucky Research Foundation Primers and probe to identify mycobacterium tuberculosis complex
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
KR100850193B1 (ko) * 2004-08-28 2008-08-04 주식회사 진인 모든 세균의 감별을 위한 세균 특이적, 속 특이적 및 종특이적 올리고뉴클레오티드, 이를 포함하는 진단 키트, 및이를 이용한 검출 방법
ES2393302T3 (es) * 2004-09-30 2012-12-20 Innogenetics N.V. Detección, identificación y diferenciación de la especie serratia utilizando la región intergénica
JP4813215B2 (ja) * 2005-03-08 2011-11-09 三星電子株式会社 プローブセットの設計方法、それにより設計されたプローブセット、前記プローブセットを備えるマイクロアレイ、前記方法をコンピュータが実行可能にするプログラムを記録したコンピュータ読み取り可能な記録媒体、および前記プローブセットを利用した標的配列の同定方法
WO2006111028A1 (fr) * 2005-04-21 2006-10-26 Uti Limited Partnership Reaction en chaine de la polymerase (pcr) pour typage sccmec mrsa
US7855051B2 (en) * 2005-09-12 2010-12-21 Research & Diagnostic Systems, Inc. Mycoplasma detection method and composition
US7819615B2 (en) * 2005-12-06 2010-10-26 Hewlett-Packard Development Method and apparatus for finishing sheets for a bound document
US7531309B2 (en) 2005-12-06 2009-05-12 Michigan State University PCR based capsular typing method
KR100707213B1 (ko) * 2006-03-21 2007-04-13 삼성전자주식회사 마이크로어레이용 프로브 선택 방법 및 장치
RU2404255C2 (ru) * 2006-05-16 2010-11-20 Кирин Бир Кабусики Кайся Набор праймеров для использования при детекции дрожжей рода dekkera и дрожжей рода brettanomyces
RU2348695C2 (ru) 2006-05-23 2009-03-10 Закрытое акционерное общество "Молекулярно-медицинские технологии" Дифференцирующий и специфический олигонуклеотиды для идентификации последовательностей днк инфекционных агентов в биологических материалах, способ видовой идентификации инфекционных агентов, биочип и набор для осуществления этого способа
WO2008084888A1 (fr) * 2007-01-08 2008-07-17 Medigenes Co., Ltd Puce d'adn permettant la détection d'escherichia coli
EP2126138A4 (fr) * 2007-01-08 2011-01-19 Medigenes Co Ltd Puce à adn pour la détection de staphylococcus aureus
EP2503008B1 (fr) 2007-04-19 2015-04-01 Molecular Detection Inc. Méthodes, compositions et kits de détection et d'analyse de bacteries resistantes aux antibiotiques
ITMI20071410A1 (it) * 2007-07-13 2009-01-14 Univ Firenze Test in biologia molecolare su campioni biologici per la diagnosi e tipizzazione di germi causa di malattie invasive
CA2720292A1 (fr) * 2008-04-01 2009-10-08 Metametrix Clinical Laboratory Procede et methode pour surveiller un microbiote gastro-intestinal
US20090253128A1 (en) * 2008-04-03 2009-10-08 Centers For Disease Control Department Of Healthy Nucleotide sequence for identifying of acinetobacter bacteria, and method and kit of identification of acinetobacter bacteria
RU2570562C2 (ru) * 2008-11-07 2015-12-10 ДюПон НЬЮТРИШН БАЙОСАЙЕНСИЗ АпС Последовательности crispr бифидобактерий
WO2010068802A1 (fr) * 2008-12-10 2010-06-17 University Of Washington Analyse ratiométrique de pré-arnr
RU2455364C2 (ru) * 2010-07-02 2012-07-10 Федеральное государственное образовательное учреждение высшего профессионального образования "Белгородская государственная сельскохозяйственная академия" Способ идентификации микобактерий с помощью полимеразной цепной реакции
RU2486251C2 (ru) * 2011-08-25 2013-06-27 Учреждение Российской академии наук Институт биохимии им. А.Н. Баха РАН (ИНБИ РАН) Способ идентификации и дифференциации прокариотических организмов
TWI614345B (zh) 2012-06-22 2018-02-11 Taichung Veterans General Hospital 檢測數種非結核分枝桿菌、結核分枝桿菌及其抗藥性之探針、晶片、套組與方法
PL223163B1 (pl) * 2012-10-04 2016-10-31 Gdański Univ Medyczny Zestaw sond i starterów do wykrywania bakterii z gatunku Acinetobacter baumannii, sposób oraz zestaw do analizy próbek medycznych i środowiskowych
TWI470083B (en) * 2012-10-23 2015-01-21 Oligonucleotide probe and biochip for identifying mycobacteria and the identification method thereof
CN109929937B (zh) * 2019-04-01 2023-04-21 广东省科学院动物研究所 龟嗜皮菌特异性鉴定引物、试剂盒及其鉴定方法
CN111647675A (zh) * 2020-06-03 2020-09-11 张家口富熙生物科技有限公司 一种用于rna恒温扩增检测布氏杆菌的引物和探针、试剂盒及检测方法
RU2765829C1 (ru) * 2021-04-27 2022-02-03 Федеральное государственное бюджетное образовательное учреждение высшего образования «Казанская государственная академия ветеринарной медицины имени Н.Э. Баумана» (RU) Набор высокоспецифичных олигонуклеотидных праймеров и зондов для детекции и дифференциации нетуберкулезных микобактерий

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US571095A (en) * 1896-11-10 Air-brake
FR651505A (fr) 1928-03-20 1929-02-20 Dispositif de blocage pour tambours d'enroulement
US4508823A (en) * 1980-05-08 1985-04-02 Microlife Technics, Inc. Gene splicing method and products produced therefrom
DK275685D0 (da) * 1985-06-18 1985-06-18 Benzon As Alfred Stabilisering af biologiske systemer
US5212059A (en) * 1988-01-11 1993-05-18 Microprobe Corporation Oligonucleotide probes for the detection of periodontal pathogens
AU623889B2 (en) * 1988-04-20 1992-05-28 Fuso Yakuhin Kogyo Kabushiki Kaisha Method for diagnosis of infectious diseases and method of detecting and identifying microorganisms
IE81145B1 (en) * 1989-04-20 2000-05-03 Thomas Gerard Barry Generation of specific probes for target nucleotide sequences
FR2651505B1 (fr) * 1989-09-06 1994-07-22 Pasteur Institut Fragments d'acides nucleiques derives d'un genome de mycobacterie appropriee, leurs applications dans le diagnostic des infections a mycobacteries et plasmides contenant lesdits fragments.
CA2033718A1 (fr) * 1990-01-19 1991-07-20 Ronald M. Atlas Procede de detection d'agents pathogenes microbiens dans l'eau et indicateurs de contamination par des matieres fecales humaines dans des echantillons d'eau et trousses de detection connexes
EP0452596A1 (fr) * 1990-04-18 1991-10-23 N.V. Innogenetics S.A. Sondes d'hybridation provenant de régions d'espacement entre les gènes de rRNA 16S et 23S pour la détection des micro-organismes non viraux
US5536638A (en) * 1990-04-18 1996-07-16 N.V. Innogenetics S.A. Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of Neisseria gonorrhoeae
US5627032A (en) * 1990-12-24 1997-05-06 Ulanovsky; Levy Composite primers for nucleic acids
EP0497464A1 (fr) 1991-01-31 1992-08-05 Amoco Corporation Diagnose rapide de microbes par hybridisation in situ en suspension aqueuse
ZA92278B (en) * 1991-02-01 1992-10-28 Akzo Nv 3-quinuclidine derivatives
US5521300A (en) * 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
FR2683227B1 (fr) * 1991-10-31 1994-03-04 Pasteur Institut Sequences nucleotidiques hybridant avec les souches bacteriennes du complexe mycobacterium avium-intracellulare, leur utilisation comme amorces oligonucleotidiques et sondes nucleiques.
IL103935A0 (en) * 1991-12-04 1993-05-13 Du Pont Method for the identification of microorganisms by the utilization of directed and arbitrary dna amplification
US5631130A (en) * 1994-05-13 1997-05-20 Abbott Laboratories Materials and methods for the detection of Mycobacterium tuberculosis
US5712095A (en) * 1994-06-16 1998-01-27 Becton Dickinson And Company Rapid and sensitive detection of antibiotic-resistant mycobacteria using oligonucleotide probes specific for ribosomal RNA precursors
EP0769068B1 (fr) * 1994-06-24 2005-10-12 Innogenetics N.V. Detection, identification et differentiation simultanees de taxa d'eubacteriales a l'aide d'une technique d'hybridation
WO1996019585A1 (fr) * 1994-12-20 1996-06-27 Heidelberg Repatriation Hospital Typage de micro-organismes
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5849488A (en) * 1996-02-27 1998-12-15 Oulutech Ltd. DNA-sequence-based diagnosis of mastitis from a milk sample

Also Published As

Publication number Publication date
US20050142575A1 (en) 2005-06-30
HK1037687A1 (en) 2003-09-17
EP1088899A2 (fr) 2001-04-04
DE69535923D1 (de) 2009-04-09
EP1091004A2 (fr) 2001-04-11
US6811978B2 (en) 2004-11-02
EP1098006A1 (fr) 2001-05-09
ES2323161T3 (es) 2009-07-08
EP1088899A3 (fr) 2001-05-02
EP0769068B1 (fr) 2005-10-12
ATE423853T1 (de) 2009-03-15
CA2193101C (fr) 2010-03-23
DK0769068T3 (da) 2006-02-27
EP0769068A1 (fr) 1997-04-23
AU2924695A (en) 1996-01-19
ES2250971T3 (es) 2006-04-16
US20030215802A1 (en) 2003-11-20
JPH10501976A (ja) 1998-02-24
CA2193101A1 (fr) 1996-01-04
DE69534516D1 (de) 2005-11-17
EP1091004A3 (fr) 2001-04-18
RU2154106C2 (ru) 2000-08-10
WO1996000298A1 (fr) 1996-01-04
ATE306560T1 (de) 2005-10-15
US6025132A (en) 2000-02-15
BR9508101A (pt) 1997-12-30
CZ381996A3 (cs) 1998-04-15
DE69534516T2 (de) 2006-06-29
US7390623B2 (en) 2008-06-24
US6312903B1 (en) 2001-11-06
EP1098007A1 (fr) 2001-05-09
CZ291483B6 (cs) 2003-03-12
JP3833703B2 (ja) 2006-10-18

Similar Documents

Publication Publication Date Title
EP1091004B1 (fr) Détection, identification et differentiation simultanées d'espèces de Mycobacterium a l'aide d'une technique d'hybridation
JP3015462B2 (ja) リステリア検出のためのプローブ類及び方法
JP4771755B2 (ja) オリゴヌクレオチド、オリゴヌクレオチドを用いた真核生物の検出方法及び同定方法
US5681705A (en) Amplification and detection of mycobacterium avium complex species
CA2142156C (fr) Sequences d'acide nucleique specifique a mycobacterium kansasii
US6074820A (en) Detection and differentiation of mycobacterium tuberculosis complex bacteria by direct variant repeat oligotyping
EP0823484A1 (fr) Matières et méthodes de détection spécifique à l'espèce d'acides nucléiques de Mycobacterium kansasii
US7160701B2 (en) Genes for detecting bacteria and a method for detecting bacteria by using the genes
US7439022B2 (en) Nucleic acids for detection of Listeria
AU723742B2 (en) Simultaneous detection, identification and differentiation of eubacterial taxa using a hybridization assay
WO1998010093A1 (fr) Sondes d'oligonucleotides permettant de detecter des bifidobacteries
Manceau et al. Assessment of subtractive hybridization to select species and subspecies specific DNA fragments for the identification of Xylophilus ampelinus by polymerase chain reaction (PCR)
US20020081606A1 (en) Methods for detecting and identifying a gram positive bacteria in a sample
AU2003220730B2 (en) Genes for detecting bacteria and detection method by using the same
KR20000075178A (ko) 마이코박테리움 포튜이튬의 내부전사지역의 염기서열
KR20000075182A (ko) 마이코박테리아 및 그 균종의 진단 방법 및 진단하기 위한 프로브
KR20000075181A (ko) 마이코박테리아균종의 진단프로브 및 진단방법
KR20000075179A (ko) 마이코박테리움 첼로네의 내부전사지역의 염기서열
KR20000075180A (ko) 마이코박테리아의 진단도구 및 진단방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 769068

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20011008

AKX Designation fees paid

Free format text: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20070205

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: SIMULTANEOUS DETECTION, IDENTIFICATION AND DIFFERENTIATION OF MYCOBACTERIUM SPECIES USING A HYBRIDIZATION ASSAY

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0769068

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69535923

Country of ref document: DE

Date of ref document: 20090409

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2323161

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090225

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090525

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090225

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090812

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

26N No opposition filed

Effective date: 20091126

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1037687

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090623

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140618

Year of fee payment: 20

Ref country code: IE

Payment date: 20140625

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20140618

Year of fee payment: 20

Ref country code: CH

Payment date: 20140618

Year of fee payment: 20

Ref country code: DE

Payment date: 20140619

Year of fee payment: 20

Ref country code: ES

Payment date: 20140627

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20140620

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140619

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140630

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69535923

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20150623

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20150622

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150622

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150624

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150623